PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 213/81, 213/89, C07C 233/77, A61K 31/44 — A1

(11) International Publication Number: **WO 97/00245**

(43) International Publication Date: 3 January 1997 (03.01.97)

(21) International Application Number: PCT/US95/07766

(22) International Filing Date: 14 June 1995 (14.06.95)

(71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; Suite 510, 2150 Shattuck Avenue, Berkeley, CA 94704 (US).

(72) Inventors: RAYMOND, Kenneth; 99 Whitaker Avenue, Berkeley, CA 94708 (US). XU, Jide; Apartment A, 1704 Francisco Street, Berkeley, CA 94703 (US).

(74) Agent: HEINES, M., Henry; Townsend and Townsend and Crew, Steuart Street Tower, One Market Plaza, San Francisco, CA 94105-1492 (US).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, ARIPO patent (KE, MW, SD, SZ, UG), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: 3-HYDROXY-2(1H)-PYRIDINONE CHELATING AGENTS



(57) Abstract

Disclosed is a series of improved metal chelating agents, selected from the group consisting of: (2), (3) or (4) which are highly effective upon both injection and oral administration; several of the most effective are of low toxicity. These chelating agents incorporate within their structure 1-hydroxy-2-pyridinone(1,2-HOPO) and 3-hydroxy-2-pyridinone(3,2-HOPO) moieties with a substituted carbamoyl group ortho to the hydroxy or oxo groups of the hydroxypyridinone ring. The electron-withdrawing carbamoyl group increases the acidity of the hydroxypyridinones. In the metal complexes of said chelating agents, the amide protons form very strong hydrogen bonds with its adjacent HOPO oxygen donor, making these complexes very stable at physiological conditions. The terminal N-substituents provide a certain degree of lipophilicity to said 3,2-HOPO, increasing oral activity. Also disclosed is a method of making the chelating agents and a method of producing a known compound, 3-hydroxy-1-alkyl-2(1H)-pyridinone, used as a precursor to the chelating agent, safely and in large quantities.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia
AT	Austria
AU	Australia
BB	Barbados
BE	Belgium
BF	Burkina Faso
BG	Bulgaria
BJ	Benin
BR	Brazil
BY	Belarus
CA	Canada
CF	Central African Republic
CG	Congo
CH	Switzerland
CI	Côte d'Ivoire
CM	Cameroon
CN	China
CS	Czechoslovakia
CZ	Czech Republic
DE	Germany
DK	Denmark
EE	Estonia
ES	Spain
FI	Finland
FR	France
GA	Gabon
GB	United Kingdom
GE	Georgia
GN	Guinea
GR	Greece
HU	Hungary
IE	Ireland
IT	Italy
JP	Japan
KE	Kenya
KG	Kyrgystan
KP	Democratic People's Republic of Korea
KR	Republic of Korea
KZ	Kazakhstan
LI	Liechtenstein
LK	Sri Lanka
LR	Liberia
LT	Lithuania
LU	Luxembourg
LV	Latvia
MC	Monaco
MD	Republic of Moldova
MG	Madagascar
ML	Mali
MN	Mongolia
MR	Mauritania
MW	Malawi
MX	Mexico
NE	Niger
NL	Netherlands
NO	Norway
NZ	New Zealand
PL	Poland
PT	Portugal
RO	Romania
RU	Russian Federation
SD	Sudan
SE	Sweden
SG	Singapore
SI	Slovenia
SK	Slovakia
SN	Senegal
SZ	Swaziland
TD	Chad
TG	Togo
TJ	Tajikistan
TT	Trinidad and Tobago
UA	Ukraine
UG	Uganda
US	United States of America
UZ	Uzbekistan
VN	Viet Nam

TITLE OF INVENTION

3-HYDROXY-2(1H)-PYRIDINONE CHELATING AGENTS

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY-SPONSORED RESEARCH AND DEVELOPMENT

This application is a continuation-in-part of an earlier filed application entitled "1,4-Disubstituted 3-Hydroxy-2(1H)-Pyridinone Chelating Agents," serial number 08/227,96, filed 04/13/94, herein incorporated by reference.

The Government has rights in this invention pursuant to Contract No. DE-AC03-76SF00098 awarded by the U.S. Department of Energy. The uranium and plutonium chemistry is supported through DOE. The iron chemistry is supported on the Berkeley campus by NIH grants AI 11744 and DK 32999. The plutonium decorporation and ligand toxicology are supported by NIEHS grant ES 02698.

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

The present invention relates generally to improved therapeutic metal chelating agents which are highly effective and have low toxicity upon injected and oral administration, and in particular to chelating agents which incorporate within their structures 1-hydroxy-2-pyridinone (1,2-HOPO) and 3-hydroxy-2-pyridinone (3,2-HOPO) moieties with a carbamoyl group substituted on the ring carbon atom ortho to the hydroxy or oxo group of the HOPO ring.

DESCRIPTION OF RELATED ART INCLUDING INFORMATION DISCLOSED UNDER §§ 1.97-1.99

Siderophores are highly selective and effective ferric chelating agents synthesized and released by microorganisms to ensure the presence of sufficient iron in solubilized form for cell reproduction. It was recognized early on that the affinity and selectivity of the siderophores for ferric ion made these compounds good candidates for therapeutic iron removal agents. This is particularly true for patients who suffer from blood diseases such as beta thalassemia, the treatment of which requires the regular transfusion of whole blood and results in the accumulation of massive tissue iron deposits. Because of the similarity in coordination properties between Fe(III) and tetravalent actinides, tetravalent actinides have great affinity for electron-donor groups that bind Fe(III), and follow Fe(III) in mammalian iron transport and storage systems. The great affinity and specificity of the siderophores towards Fe(III) suggest that modification of siderophores, which are effective sequestering agents for ferric ion, would yield potential chelators of tetravalent actinides, which present significant biological hazards associated with nuclear technology. Following absorption, the actinide cations that have been inhaled, ingested, or deposited in a wound circulate in serum

bound to transferrin (Tf), the iron transport protein, and renal and gastrointestinal excretion are severely inhibited. As actinide-containing cells and structures die, the released actinide is recirculated, and nearly all of it is re-deposited at new sites. The alpha particles emitted by the actinides kill cells and induce cancer in the major storage tissues--lung, bone, liver. The only known way to reduce the toxicity of these radioactive metals is to use chelating agents to accelerate their excretion, thereby preventing deposition or re-deposition. Normally, such actinide chelating agents will be octadentate ligands, as opposed to the generally hexadentate or tetradentate siderophores. Other uses, such as radionuclide chelation in nuclear medicine applications, for example, are also clearly possible.

The biomimetic approach of the present invention, which designs and synthesizes sequestering agents for ferric ion and actinides, are based on siderophores. The metal binding units of siderophores are usually either catechols (dihydroxybenzene analogues; Formula 1A) or hydroxamic acids (Formula 1B):



Formula 1A



Formula 1B

In fact, desferrioxamine B (DFO), a tri-hydroxamic acid siderophore, is used as a human iron sequestering agent. This chelating agent has predominated for over 30 years as the method of choice for treatment of iron overload. However, DFO has low oral activity and a number of adverse effects: including administration via a cumbersome subcutaneous infusion, leading to poor patient compliance with the treatment regime, and poor efficacy in removing deposited actinides. As a result of these limitations of the prior art drugs, there is a need for more effective and orally active iron sequestering agents to treat iron overload as well as actinide poisoning.

The most potent natural Fe(III) chelator is enterobactin, a siderophore produced by enteric bacteria with a formation constant of $K_f = 10^{49}$, pM = 35.5. This hexadentate ligand is composed of three catechoylamide groups attached to a tri-serine lactone backbone. Catecholates are much stronger sequestering agents than hydroxamate ligands, such as DFO, and these ligands are faster in removing iron from human transferrin, primarily for kinetic rather than thermodynamic reasons. Synthetic analogues of catechol-based siderophores are also known. However, there are a number of difficulties in developing catecholates into effective pharmaceutical agents. A number of catecholate siderophores, including enterobactin, will be bound by albumin in serum. They also strongly promote the growth of pathogenic microorganisms. The weak acidity of catechol and the required loss of two protons per catechol group at or about neutral pH limit the effectiveness of catechol-based ligands *in vivo*. These factors place severe limitations on the use of catechol-based ligands as therapeutic agents. It is therefore desirable to provide a medicinally useful metal chelating agent having a higher K_a, i.e., more acidic, and which therefore binds more effectively at physiological pH, than catechol-based compounds. Uninegative ligands, i.e., ligands having a single negative charge near neutral pH range, are particularly desirable, in contrast to the correspondingly highly charged ferric and plutonium catechol complexes.

Derivatives of hydroxypyridinones ("HOPO") are of particular interest, since these ligands selectively display high affinity for ferric and actinide ion. These ligands and their mono-anions have a zwitteronic resonance form that is isoelectronic with the catechol dianion. The abbreviation "HOPO" will hereinafter be used to include hydroxypyridinone analogues as well as isomers or tautomers thereof, in either protonated or deprotonated forms.

The HOPO ligands have been shown to be very promising sequestering agents. The bidentate 3,4-HOPO ligand, 1,2-dimethyl-3-hydroxy-4-pyridinone, is orally active and has gone through extensive study, including clinical trials. However, there are many limitations for such a simple bidentate ligand. Multidentate HOPO derivatives have advantages over

simpler bidentate ligands: in particular, low toxicity resulting from a higher binding affinity (pM) at low (clinical level) ligand concentrations.

Previous patents on hydroxypyridone ligands used as chelating agents include "Hydroxypyridonate Chelating Agents", US Patent Number 4,698,431, patented by Kenneth N. Raymond, Robert C. Scarrow, and David L. White, October 6, 1987. This invention provided 1,2-HOPO derivatives with either an amide or a carboxylic acid moiety in the number 6 position. These chelating agents are useful in selectively removing certain cations from solution and are particularly useful as ferric ion and actinide chelators. However, Patent Number 4,698,431, did not claim other chelating agents having 3,2-HOPO moieties incorporated within their structures or a carboxy moiety on the number 3 position of 1,2-HOPO ring.

Other related art includes Pharmaceutical Compositions of Hydroxypyridones, US patent number 4,666,927, patented by Robert C. Hider, George Kontoghiorghes, Jack Silver, and Michael A. Stockham, May 19, 1987. Claim 1 of this patent claims a number of possible chelating agents having 1,2-HOPO, 3,2-HOPO, or 3,4-HOPO moieties incorporated within their structures that are linked through a number of possible combinations of linking groups, including -CONH- groups. However, US Patent Number 4,666,927 teaches against a HOPO moiety having a substitution ortho to the hydroxy or oxo group of the HOPO ring.

In contrast to US patent number 4,666,927, the inventors have developed a new design strategy, that is to synthesize a new series of 3,2-HOPO derivatives with either a carboxylic acid or a (substituted) carbamoyl moiety substituted on the ring carbon ortho to the HOPO hydroxy group. The particular coordination geometry and the hydrogen bonding between the amide proton and HOPO oxygen donor in these HOPO-metal complexes disclosed by the present invention thereby make the new series of 3,2-HOPO derivatives unusually good complexing agents having very high stability and specificity towards metal binding. The inventors further found these new compounds have stronger acidity and

chelating ability for iron and actinides and have high oral activity in removing toxic actinides *in vivo*.

Furthermore, the method of synthesizing the present invention having 3,2-HOPO moieties incorporated within their structures with the (substituted) carbamoyl group ortho to hydroxy group of HOPO ring is not obvious. One earlier attempt by the inventors included: reacting 4-carboxy-3-hydroxy-2(1H)-pyridinones (Formula 9A) with 1,1'-carbonyldiimidizole to produce the active amide intermediate, which is then reacted with backbone amines to form the corresponding novel 3,2-HOPO ligands, similar to the case of thiohydroxamate. See. e.g., Kamal Abu-Dari and Kenneth N. Raymond, "Ferric Ion Sequestering Agents. 23. Synthesis of Tris(hydroxypyridinethione) Ligands and Their Ferric Complexes; X-ray Structure Analysis of N,N',N"-Tris(1,2-didehydro-1-hydroxy-2-thioxopyrid-6-yl)carbonyl)-2,2',2"-triaminotriethylaminato)iron(III)," *Inorg. Chem.* 1991, *30*, 519-524. However, the purification of the final product is difficult, therefore, this method is not preferred. A second attempt to carry out the above reaction produced the acid chloride of 1-alkyl-4-carboxy-3-hydroxy-2(1H)-pyridinone as an active intermediate using thionyl chloride or oxalyl chloride, similar to the case of catechoylamide ligands. Due to the low yield of compound in preliminary tests, this method is also not preferred.

The present invention discloses a process to synthesize the desired multidentate 1,2-HOPO and 3,2-HOPO ligands in good yield.

Accordingly the present invention comprises an effective multidentate siderophore analogue HOPO ligand in which one or more HOPO rings are linked to a molecular backbone through amide linkage. The inventors have previously reported the synthesis of siderophore analogues with linear, multipodal and macrocyclic topologies, and have shown a more effective ligand is one with a greater predisposition toward binding. In the design of the present invention, these synthetic strategies, as well as the binding abilities, solubility and lipophilicity of the resulted compounds, are important factors considered.

SUMMARY OF THE INVENTION

The present invention represents a breakthrough in siderophore-like ligands intended for pharmaceutical use. The present invention provides novel 1,2-HOPO and 3,2-HOPO chelating agents capable of selectively forming stable complexes with certain cations such as Fe^{3+}, Gd^{3+}, Am^{3+}, Pu^{4+}, Np^{4+}, and U^{6+} ions.

The present invention allows this highly advantageous class of chemicals to be administered orally or by injection.

These complexing agents are lipophilic enough to display oral activity.

The present invention provides a method to produce these compounds safely and in good yield.

The present invention provides unusually good complexing agents with high stability and specificity for iron and actinides.

The present invention provides chelating agents which are relatively acidic and incorporate monoprotic ligand groups.

The present invention provides methods of using the novel chelating agents.

The present invention provides methods of synthesizing the novel chelating agents. These new HOPO ligands are generally synthesized by introducing a carboxylate group at the carbon atom ortho to the ligating group of HOPO ring, then making an amide linkage to a suitable molecular backbone.

In one aspect of the invention, novel chelating agents are provided which include HOPO-based bidentate and multidentate ligands, as well as mixed multidentate ligands such as HOPO-substituted desferrioxamine. In other aspects of the invention, novel methods of synthesizing the HOPO-derived chelating agents are provided, as are methods of using the novel compounds.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel 1,2-HOPO and 3,2-HOPO chelating agents capable of selectively forming stable complexes with certain cations such as Fe^{3+}, Gd^{3+}, Am^{3+} and Pu^{4+}, Np^{4+}, and U^{6+} ions. Accordingly the present invention comprises a compound consisting of 4-(substituted)carbamoyl-3-hydroxy-2-pyridinones having optional substituents on the nitrogen atom, and on one or more of the carbon atoms of the ring. Shown below are the preferred basic ring system in the compounds of the present invention (Formula 2), the basic ring system of 1,2-HOPO-6-carbamoylamide (Formula 3), and catechoylamide (Formula 4):



Formula 2



Formula 3



Formula 4

wherein R_1 and R_2 are separately selected from the group consisting of: hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, or carboxy group or an aryl group.

The HOPO rings are attached to a molecular or polymeric backbone R through amide linkages, where R is selected from multi-linking groups. Representative examples of such multi-linking groups include, but are not limited to:



Formula 5A
(m = 1-3, n = 1-3, p = 1-3)



Formula 5B
(m = 1-3, n = 1-3, p = 1-3)

Formula 5C
(m = 1-6)



Formula 5D
(R" = H, alkyl)



Formula 5E
(m = 1,2)



Formula 5F



Formula 5G
(m = 1-2)



Formula 5H
(m = 2-6, q = 2-4)

wherein the several X's of a formula may be a combination of chelating agents selected from the group consisting of:



Formula 5I



Formula 5J

or



Formula 5K

and Y is a 3,2-HOPO or 1,2-HOPO structural unit selected from the group consisting of:



Formula 5L



Formula 5M

or



Formula 5N

where the free valency in each case indicates the preferred attachment point of the chelating group to a backbone.

In Formulae 5A to 5H, some of the chelating units X and Y may also be substituted by other chelating structural units. Representative examples of other chelating units include, but are not limited to: aminoacetic acid, hydroxamic acid, catechol, 2,3-dihydroxyterephthalamide or 3,4-HOPO.

Due to the presence of electron-withdrawing substituted carbamoyl group ortho to the hydroxy group of HOPO ring, compounds of Formulae 3 and 4 have lower pK_as and more preferable coordination properties than corresponding HOPO ligands without the carbamoyl substituents. Their ring systems are also more able to withstand reduction or oxidation than corresponding HOPO ligands without the carbamoyl substituents. Similar to the case of catechoylamide complexes (Formula 6) and 1,2-HOPO-6-ylamide complexes (Formula 7), the strong hydrogen bonding between the amide proton and the adjacent oxygen donor, the hydroxy oxygen atom, also enhances the stability of the 3,2-HOPO complexes of this invention (Formula 8) as shown below:





Formula 6 Formula 7 Formula 8

wherein M is a metal ion with a high charge to radius ratio and the free valency in each case indicates the preferred attachment point of the chelating group to a backbone.

These chelating agents become very powerful chelators for metal ions with high charge to radius ratios.

Another important feature of the 3,2-HOPO ligands of this invention is that these compounds have a terminal R_1 group substituted on the HOPO ring nitrogen, which provides certain adjustable lipophilicity to the whole molecule, necessary for the ligand to display oral activity.

The lipophilic properties of the HOPO substituted compounds in combination with their relatively low pK_as make them effective oral agents, a highly desirable property for therapeutic agents. The new 3,2-HOPO compounds display high binding constants for ferric ion, on the order of 10^{26} to 10^{29} M^{-3}, and pM values from 19 to 27 for the Fe(III)-tris(HOPO) complexes and are thus effective ligands for iron as well as for certain other ions with similar coordination properties (e.g., the actinide(IV) ions). These ligands are also surprisingly good chelating agents for the lanthanides.

Monomeric bidentate compounds of the invention include those given by the structure of Formula 9A, 9B and 9C.



Formula 9A



Formula 9B



Formula 9C

Formula 9A shows the acid form, while Formulae 9B and 9C show the benzyl protected amide form and deprotected amide form respectively. In these forms, R_1 is selected from the group consisting of: hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, or carboxy group or an aryl group. When R_1 is selected from these groups, the molecule is provided with adjustable lipophilicity. In Formula 9B and 9C, R' is selected from the group consisting of: hydrogen, C_{1-8} aliphatic hydrocarbon groups, and C_{1-8} aliphatic hydrocarbon groups substituted by a single carboxy, sulpho, sulphamoyl, N-methyl or N-ethyl sulphamoyl group, or an aryl group. The free valency in each case indicates the preferred attachment point of the chelating group to a backbone. Optionally, formulae 9A and 9C are in the form of a physiologically acceptable salt.

Although the new HOPO monomers display high affinity for ferric ions, for example, 1-methyl-4(1-propylcarbamoyl)-3-hydroxy-2(1H)-pyridinone (Formula 9C, backbone = n-propyl, R' = H, R_1 = methyl), it has overall complex binding constants on the order of $10^{28.7}$ M^{-3} for Fe(III). However, because of the 3:1 stoichiometry of the bidentate monomer /Fe complex, its stability is strongly dependent on its concentration (by the 3rd power). Generally, the pM concept was used to define the concentration of unchelated metal ion at physiological pH (7.4), and at chelator and metal ion concentrations (μmolar range) which are those expected in the plasma of a chelator-treated patient. The more effective chelator has the larger pM value. Since the multidentate 3,2-HOPO ligands have higher pM values than their bidentate analogues, they have stronger scavenging power for

iron and actinides *in vivo*. For example, the bidentate compound 1-methyl-4(1-propylcarbamoyl)-3-hydroxy-2(1H)-pyridinone has a pM of 19.26 for Fe(III), while the hexadentate compound TREN-Me-3,2-HOPO (Formula 12, m=1) has a pM of 26.69 for Fe(III).

Tetradentate chelating agents of the present invention, which incorporate two 3,2-HOPO structural units, are given by Formula 10. These compounds form stable 2:1 complexes with actinides, and are promising actinide sequestering agents.



Formula 10.

In Formula 10, two 3,2-HOPO structural units are linked to an aliphatic hydrocarbon molecular backbone $-(CH_2)_m-$, R_1 is as given above for the monomers of Formula 9, and m is an integer from 2 to 9. In a particularly preferred form, m is five, and the structure is "5-LI-Me-3,2HOPO" (1-Methyl-3-hydroxy-2(1H)-pyridinone structures separated by five methylene groups, some-what analogous in structure to previously known 5-LICAM, i.e. linear catechoylamide sequestering agents). Alternative molecular backbones of special interest are groups corresponding to a hydrocarbon group in which one or more carbon atoms are replaced by an oxygen or nitrogen atom. Such backbones are preferably more hydrophilic and the corresponding ligands will have better solubility in water. Specific examples of such tetradentate ligands are given by Formula 11, in which R_1 is as given above for the



Formula 11

monomers of Formula 9, and m and n are each an integer from 2 to 4, and X may be oxygen or nitrogen (with a hydrogen, alkyl or aryl substitution).

Since hexadentate chelating agents form 1:1 complexes with iron, their stability has first order dependence on the ligand concentration. In other words, the hexadentate 3,2-HOPO ligands have strong scavenging power for iron at low concentration of ligand. The inventors surprisingly notice that the new tetradentate and hexadentate 3,2-HOPO ligands are not only excellent iron sequestering agents but also excellent actinide sequestering agents *in vivo*. This is surprising because actinides have coordination numbers greater than eight and therefore would not be expected to bind well to tetradentate or hexadentate chelating agents. This is not the case for tetradentate CAM or 1,2-HOPO sequestering agents, which are toxic and less effective *in vivo*.

Furthermore, because the new HOPOs are such effective chelators, it is possible that they can be used as MRI diagnosis complexing agents. As a specific example, see example 20, *infra*.

Hexadentate chelating agents of the present invention which incorporate three 3,2-HOPO structural units with a tripodal amine backbone are given by Formula 12 and 13. In both Formulae, R_1 is as given above for the monomers of Formula 9; and in Formula 12, m is an integer from 1 to 3.



Formula 12



Formula 13

Compounds of Formula 12 with m = 1 represents a particularly preferred embodiment of the invention, as it has been demonstrated to be non-toxic and extremely effective both in ferric chelation and in the decorporation of actinides such as Pu(IV), Am(III) and U(VI). This structure is abbreviated as TREN-Me-3,2-HOPO, similar in structure to previously known triscatechoylamide ligand TRENCAM.

Octadentate chelating agents provided by the present invention which incorporate four 3,2-HOPO structural units are given by Formula 14. This design is based on the siderophore analogues with 'H' shaped tetrapodal topology developed by the inventors, which proved to be predisposed towards metal binding. These chelating agents are especially suitable for binding actinide (IV) ions, because of their preferred high coordination number (eight or greater).



Formula 14

In Formula 14, R_1 is as given above for the monomers of Formula 9, and m and n are each an integer from 1 to 4.

The chelating agents of this invention also include mixed HOPO ligands which in addition to having at least one 3,2-HOPO structural unit, may also have other chelating structural units. Examples of these mixed chelating agents given by Formulae 15-17.



Formula 15



Formula 16



Formula 17

Formula 15 gives a 3,2-HOPO-substituted analogue of ethylenediamine-N,N,N',N'-tetraacetic acid (EDTA) and Formula 16 gives a 3,2-HOPO substituted diethylenetriamine analogue with the Z moiety which is selected from the group consisting of: hydrogen, C_{1-40} hydrocarbon groups, 2-hydroxyethyl, 2-aminoethyl, and C_{1-4} aliphatic hydrocarbon groups substituted by a single carboxy, sulpho, acrylamido or an aryl group; Formula 17 gives a 3,2-HOPO-substituted analogue of desferrioxamine-B. In Formulae 15-17, R_1 is also as given above for the monomers of Formula 9. The chelating agent of Formula 16 with a long hydrocarbon chain as the Z group is a promising extractant for actinides, especially Am(III).

The chelating agents of this invention also include amine compounds which, in addition to having at least one 3,2-HOPO structural unit, are also substituted with 1,2-HOPO analogues and catechol analogues. Thus, in the compounds of Formulae 10-16 above, the HOPO substituents could be replaced with the any of the structures given by Formulae 18 to 21, as long as one or more 3,2-HOPO substituents remain present on the chelating structure (where the free valency in each case indicates the preferred attachment point of the chelating group to a backbone).



Formula 18



Formula 19



Formula 20



Formula 21

Also included in the present invention are chelating agents having polymeric backbones and at least one amine functionality to which a HOPO substituent is bonded through an amide-type linkage. Examples of suitable polymers here include, but are not limited to, poly(styrene-divinylbenzene), agarose, and polyacrylamide.

The present invention also relates to novel methods of synthesizing the aforementioned chelating agents as outlined below.

The novel 3,2-HOPO compounds (represented below by the monomeric compound) shown in Formula 9-17 may be conveniently synthesized according to Scheme 1.

Scheme 1



Formula 22 Formula 9A Formula 23



Formula 24 Formula 25 Formula 9B Formula 9C

Wherein R = backbone, R_1 is selected from the group consisting of: hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, or carboxy group or an aryl group, and R' is selected from the group consisting of: hydrogen, C_{1-8} aliphatic hydrocarbon groups, and C_{1-8} aliphatic hydrocarbon groups substituted by a single carboxy, sulpho, sulphamoyl, N-methyl or N-ethyl sulphamoyl group, or an aryl group.

The 4-carboxylic acid derivative (Formula 9A) of 1-alkyl-3-hydroxy-2-pyridinone is prepared from a 1-alkyl-3-hydroxy-2-pyridinone . The latter, for example, 1-methyl-3-

hydroxy-2-pyridinone (Formula 22, R_1 = methyl) is a known compound. However, the reported procedure is not safe and is neither convenient nor suitable for large scale production. The reported procedure is to put 3-hydroxy-2(1H)-pyridinone and iodomethane in a sealed glass tube and heat this mixture to 140° C for two days. However, the size of the sealed glass tube is limited and yields only several grams of product. Furthermore, the pressure in the sealed glass tube may cause it to explode, thereby releasing toxic fumes. If the glass tube does not explode, the resultant material is treated with gaseous sulfur dioxide, a corrosive and toxic gas. In the final step, the compound is purified by recrystallization from petroleum ether, a method that is not safe, not convenient and is time consuming. Because Formula 9A is an important precursor to the present invention, the inventors have developed a safe and convenient procedure which can be used for large scale production as follows. 3-Hydroxy-2(1H)-pyridinone and iodomethane (1:1.5 mol ratio) are placed in a capped Teflon container, the container is put in a stainless steel Parr bomb and heated to 150° C for 2 days. This container may be 50 times larger than the sealed glass tube and will not explode. The cooled bomb is opened and the resultant thick dark oil is mixed with sodium sulfite (1:1.5 mol ratio), which is not corrosive and toxic (as is gaseous sulfur dioxide) and dissolved in water. The solution is neutralized and then extracted with a suitable solvent. The 1-methyl-3-hydroxy-2-pyridinone may then be purified with a flash silica gel plug, which is much safer, convenient and time saving than recrystallization from hot petroleum ether. The reported procedure yields approximately 6 grams each batch. The present invention can yield approximately 300 grams by using a 1 liter capacity Parr bomb each time.

The 4-carboxylic acid shown in Formula 9A (R_1 = H, alkyl) may then be prepared from the 3,2-HOPO compound of Formula 22 (R_1 = H, alkyl) as follows. A quantity of the 3-hydroxy-2(1H)-pyridinone is mixed with anhydrous alkali metal carbonate, such as sodium or potassium carbonate, in a preferred mol ratio of 1:3 to 1:5. The dried mixture is then put in a Parr bomb and the bomb is then filled with dry carbon dioxide (850 psi) and

heated to 170-200° C for 2 days. The cooled bomb is opened and the resultant solid is dissolved in water and treated with HCl, the 4-carboxylic acid may then be isolated as free acid form e.g. by filtration recrystallization and dried (see Example 1).

The 3,2-HOPO ligands shown in Formulae 9C to 17 may be preferably prepared from the reaction of an amine backbone and the active protected intermediates. Thus the 1-alkyl-4-carboxy-3-hydroxy-2(1H)-pyridinone (Formula 9A) may conveniently be converted to the protected acid (Formula 23) through the protection of the 3-hydroxy group. Protection can be performed with an ether group, such as a benzyloxy group or a methoxy group. Benzyloxy protection is preferred because it can be easily deprotected by hydrogenation. Reaction of the protected acid with a compound to activate the acid (for example: 2-mercapto-thiazoline or N-Hydroxysuccinimide (NHS)), in the presence of 1,3-dicyclohexylcarbodiimide (DCC) gives the activated intermediates (Formulae 24 or 25). This is reacted with the amine compound which will provide the "backbone" of the chelating agent at room temperature to give the protected 3,2-HOPO ligands generally as viscous oils. They are purified preferably by extraction and/or column chromatography. The hydroxy protecting groups may then be removed by hydrogenation and the final product may be recrystallized from methanol, ethyl acetate, or water.

The 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-pyridinone (Formula 24) is a highly preferable intermediate: it is a bright yellow crystalline compound, easy to be prepared and purified. Unlike other activated intermediates such as 3-benzyloxy-1-methyl-4-(succinimidyloxy)carbonyl-2(1H)-pyridinone (Formula 25), it is stable and not sensitive to alcohol, water, or even dilute inorganic acid and base. It selectively reacts with primary amines to form amide products. The end of the reaction can be easily monitored by the disappearance of its characteristic yellow color.

While many amines can be used in this reaction to effect production of 3,2-HOPO-substituted chelating agents, preferred amines are those which correspond to the structures of Formulae 9-17. Particularly preferred amines are the polyamines: 1,5-diaminopentane

$(NH_2(CH_2)_5NH_2)$, 2,2'-oxybis(ethylamine), tris(2-aminoethyl)amine (see Formula 12, m=2), tris(aminomethyl)-benzene (see Formula 13), N,N,N',N'-tetra(2-aminoethyl)ethylenediamine, also known as PENTEN (see Formula 14, m=n=2), and the monoamine desferrioxamine B (see Formula 17).

Other amines which may be used in the above synthetic procedure include compounds generally given by Formulae 10-13 but having one or more 1,2-HOPO, 3,2-HOPO and catechol moieties in addition to at least one 3,2-HOPO moiety. Organic polymers having at least one amino group may also be used (e.g., agarose, polyacrylamide, polystyrene derivatives and other similar compounds).

The novel 3,2-HOPO compounds (represented below by the monomeric compound) shown in Formula 9-17 are also conveniently synthesized according to Scheme 1-1.

Scheme 1-1

Step 1:



Formula 22A Formula 9A' Formula 9E Formula 9F

Step 2A:



Formula 9E Formula 23A Formula 24A Formula 25A



Formula 9B' Formula 9C

or Step 2B:



Formula 9F Formula 23B Formula 24B Formula 25B



Formula 9G Formula 9C'

Wherein R = backbone, R_1 is selected from the group consisting of: hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, or carboxy group or an aryl group, and R' is selected from the group consisting of:

hydrogen, C_{1-8} aliphatic hydrocarbon groups, C_{1-8} aliphatic hydrocarbon groups substituted by a single carboxy, sulpho, sulphamoyl, N-methyl or N-ethyl sulphamoyl group, or an aryl group, and W is generally Chloride, Bromide, or Iodide.

Step 1: The 4-carboxylic acid shown in Formula 9A' is prepared from the commercially available 2,3-dihydroxypyridine (Formula 22 A) as follows. A quantity of the 3-hydroxy-2(1H)-pyridinone is mixed with anhydrous potassium carbonate in a preferred mol ratio of 1:3 to 1:5. The dried mixture is then put in a Parr bomb and the bomb is then filled with dry carbon dioxide (850 psi) and heated to 200° C for 2 days. The cooled bomb is opened and the resultant solid is dissolved in water and treated with HCl, the 4-carboxylic acid is then isolated in a free acid form, for example, by filtrating recrystallizing and drying.

The 3,2-HOPO ligands shown in Formulae 9C to 17 are preferably prepared from the reaction of an amine backbone and the active protected intermediates. Thus the 4-carboxy-3-hydroxy-2(1H)-pyridinone (Formula 9A') is conveniently converted to the fully protected ester (Formula 9E and 9F) through the reaction with an alkylating agent, such as benzyl chloride or methyl iodide, in the presence of a base, such as potassium carbonate. Compounds 9E and 9F are easily separated by column chromatography.

Step 2A: Compound 9E is converted into the protected acid (Formula 23A), and reaction of the protected acid with a compound to activate the acid (for example: 2-mercapto-thiazoline or N-Hydroxysuccinimide (NHS)) in the presence of 1,3-dicyclohexylcarbodiimide (DCC) gives the activated intermediates (Formulae 24 A or 25A). This is reacted with the amine compound which will provide the "backbone" of the chelating agent at room temperature to give the protected 3,2-HOPO ligands generally as viscous oils. They are purified preferably by extraction and/or column chromatography. The hydroxy protecting groups are then removed by deprotection (for example using BBr_3 as a deprotecting agent) and the final product is recrystallized from methanol, ethyl acetate, or water.

Step 2B: Similarly, compound 9F is converted into the protected acid (Formula 23B), and reaction of the protected acid with a compound to activate the acid (for example: 2-mercapto-thiazoline or N-Hydroxysuccinimide (NHS)), in the presence of 1,3-dicyclohexylcarbodiimide (DCC) gives the activated intermediates (Formulae 24 B or 25B). This is reacted with the backbone amine compound at room temperature to give the protected 3,2-HOPO ligands generally as crystalline solids. They are purified preferably by extraction and/or column chromatography. The hydroxy protecting groups are then removed by deprotection (for example using BBr_3 as a deprotecting agent) and the final product may be recrystallized from methanol, ethyl acetate, or water. In this way a series of N-unprotected multidentate 3,2-HOPO ligands can be prepared conveniently.

Properties of the Novel Compounds

Physical Properties: The novel 3,2-HOPO compounds are white to pale-yellow in color. They are not hygroscopic in general and are obtained as micro-crystalline or amorphous solids. The monomers melt sharply, but the multidentate compounds decompose slowly upon heating. The most distinctive feature of their NMR spectra is the presence of two doublets in the aromatic region arising from the HOPO ring protons. The two doublets appear at d 6.4-6.6 and at d 6.6-7.2 ppm. The I.R. of the isolated compounds display a strong band at 1650-1680 cm-l due to the amide group. In addition to that band there are four strong bands in the region 1430-1600 cm^{-1} due to the ring C=C and C-N stretching frequencies.

Chemical Properties: The 3,2-HOPO based amide compounds are in general slightly to moderately soluble in water, except the simple monomers, such as compound 1-methyl-4(1-propylcarbamoyl)-3-hydroxy-2(1H)-pyridinone (Formula 9C, R=1-propyl, R'=H), which is very soluble in water as well as organic solvents. They are nearly neutral

(having pK_a's on the order from 5 to 8), and the pH of saturated solutions typically are close to neutral. These compounds form stable complexes with various metal ions, such as Fe^{3+}, Gd^{3+}, Am^{3+}, Pu^{4+}, etc.

Experimental Methods:

Infrared spectra were obtained with a Perkin-Elmer Model 283 spectrophotometer. The NMR spectra were obtained using UCB 250 (250 MHz), BVX 300 (300 MHz) and AM 500 (500 MHz) spectrometers. Mass spectral data were obtained with an Atlas MS11; a consolidated 12-110B, or a Kratos MS-50 spectrometer. The data can be tabulated as m/e. Elemental analyses were performed by the microanalytical Laboratory, Department of Chemistry, University of California, Berkeley.

Tris(3-aminopropyl)amine, 1,3,5-tris(aminomethyl)benzene, N,N,N',N'-tetrakis(2-aminoethyl)-ethylenediamine (PENTEN or H(2,2)-amine) can be prepared by methods described in the literature. N,N,N',N'-Tetrakis(2-aminoethyl)-1,3-propylenediamine (H(3,2)-amine), and N,N,N',N'-tetrakis(2-aminoethyl)-1,4-butylenediamine (H(4,2)amine) can be prepared in a manner similar to the preparation of PENTEN. Desferrioxamine B can be obtained from Ciba-Geigy. Other reagents and items disclosed can be purchased from Aldrich Chemical Co. and used as received.

Animal studies were completed using methods detailed in Radiation Protection Dosimetry, in press, P. W. Durbin et al., "*In Vivo* Chelation of Am(III), Pu(IV), Np(V) and U(VI) in Mice by TREN-(Me-3,2-HOPO)"; Radiation Protection Dosimetry, 17, No. 1, 1989, p. 351, P. W. Durbin et al., "Removal of ^{238}Pu(IV) from Mice by Polycatechoylate, -Hydroxamate or -Hydroxypyridinonate Ligands"; Radiation Research, 99, 1984, p. 85, P. W. Durbin et al., "Specific Sequestering Agents for the Actinides . . . "; Radiation Research, 99, 1984, p. 106, P. W. Durbin et al., "Removal of Pu and Am from Beagles and Mice . . . "; Radiation Research, 81, 1980, p. 170, R. D. Lloyd et al., and P. W. Durbin et al., "Specific

Sequestering Agents for the Actinides . . . ". The foregoing articles are hereby incorporated by reference.

Radionuclides used in the animal studies came from a variety of sources. However, they can be purchased commercially. The $^{238}Pu(IV)$ citrate and $^{241}Am(III)$ citrate solutions were prepared for animal injection by 8- to 10-fold dilution with 0.14M NaCl (pH 4) of concentrated stock solutions (0.08M sodium citrate buffer) that had been held in frozen storage at Lawrence Berkeley Laboratory (hereinafter LBL) for several years. [The $^{238}Pu(IV)$ was originally obtained from D. R. Atherton at the University of Utah Radiobiology Laboratory, Salt Lake City. The $^{241}Am(III)$ solution had been obtained many years earlier from the LBL Actinide Chemistry group.]

The $^{237}Np(V)$ was obtained from J. Bucher of the LBL Actinide Chemistry group as NpO_2Cl in 0.1M HCl. It was diluted to the desired radioactivity concentration in 0.14M NaCl and the pH was adjusted to about 4.5 with NaOH just before use.

The ^{232}U was obtained from the Isotope Products Laboratory, Burbank, CA, and $^{234,235}U$ was obtained as U metal from long held LBL storage. The two U sources were combined and dissolved in 6N HNO_3, dried, and redissolved in 0.1N HCl. The daughter radioactivities were removed by elution from a Dowex-50X4 column (22 cm length, 0.7 cm diameter, 1.5 mL·min^{-1} flow rate) with 3.2N HCl. The U fractions (previously identified by a trial run with $^{234,235}U$ alone) were combined, dried, and redissolved in 0.14M NaCl at pH 5.5.

All injections solutions, after dilution and pH adjustment, were sterilized by passing through a 0.22 µm Millipore filter into 10 mL serum bottles fitted with rubber stoppers, and frozen until used.

Solutions were calibrated by alpha scintillation counting (Packard Tri-Carb 460C, Ecolume® scintillation fluid).

The current catalogue of Isotope Products Laboratory, Burbank, CA, lists for retail sale: ^{238}Pu, ^{241}Am, ^{237}Np, and ^{232}U.

EXAMPLES

EXAMPLE 1: Preparation of 3-benzyloxy-4-carboxy-1-methyl-2(1H)-pyridinone and related precursors

(1) 1-Methyl-3-hydroxy-2(1H)-pyridinone (Formula 22, R_1=methyl):

1-methyl-3-hydroxy-2(1H)-pyridinone is a known material; however the previous procedure for preparation is neither safe nor suitable for large scale production. Therefore, the inventors have developed a safe and convenient procedure which can be used for large scale or industrial production after minor modification. The details are described as follows:

3-hydroxy-2(1H)-pyridinone (34.44 g, 0.31 mol) and iodomethane (75 g, 0.53 mol) are placed in an 80 mL capped Teflon container (Caution: iodomethane is highly toxic), and put in a stainless steel Parr bomb and heated to 150° C for about 48-60 hours. The cooled bomb is opened and the excess iodomethane decanted. The resultant thick dark oil is mixed with sodium sulfite (64 g, 0.5 mol) and dissolved in 300 mL water to form a pale brown solution. The solution is neutralized to pH 7-8 and filtered to remove any insoluble impurity. The filtrate is then extracted with methylene chloride (4 x 100 mL). The combined extracts are dried, then applied to a flash silica gel plug (6 cm x 8 cm) and eluted with 4% methanol in methylene chloride. The solvent is rotary evaporated to give the title compound (24.3 g, 62.6%) as colorless crystals, mp. 129-130° C. ^{1}H NMR (250 MHz, $CDCl_3$): δ 3.621 (s, 3H), 6.144 (t, 1H, J=7.10), 6.79-6.85 (m, 2H), 7.27 (s,br, 1H). Anal. for $C_6H_7NO_2$ (125.129), Calcd.(found): C, 57.59 (57.23); H, 5.64 (5.70); N, 11.20 (10.93).

(2) 4-Carboxy-1-methyl-3-hydroxy-2(1H)-pyridinone (Formula 9A, R_1=methyl)

1-Methyl-3-hydroxy-2(1H)-pyridinone (1) (6.25 g, 50 mmol) is mixed with anhydrous potassium carbonate (36 g, 0.26 mol). The vacuum dried mixture is put in a Parr bomb which is then filled with dry carbon dioxide gas (850 psi) and heated to 175-185° C for 3 days. The cooled bomb is opened and the resultant pale yellow solid is dissolved in

ice water and acidified with 6N HCl to produce a beige crystalline product (7.42 g, 87.5%), m.p. 243-245° C (dec). ^{1}H NMR (250 MHz, DMSO-d_6): δ 3.469 (s, 3H), 6.357 (d, 1H, J=7.33), 7.166 (d, 1H, J=7.19), 7.27 (s,br, 1H). ^{1}H NMR (250 MHz, D_2O-NaOD): d 3.342 (s, 3H), 6.176 (d, 1H, J=6.94), 6.487 (d, 1H, J=7.00). Anal. for $C_7H_7NO_4$ (169.14): Calcd. (found): C, 49.71 (49.74); H, 4.17 (4.30); N 8.28 (8.16).

(3) 3-Benzyloxy-4-carboxy-1-methyl-2(1H)-pyridinone (Formula 23, R_1=methyl)

4-Carboxy-1-methyl-3-hydroxy-2(1H)-pyridinone (6.8 g, 0.04 mol) is mixed with benzyl chloride (12.1 g, 0.088 mol), anhydrous potassium carbonate (13.8 g, 0.1 mol) in anhydrous dimethyl-formamide (DMF) (120 mL). The mixture is heated at 75-80° C under N_2 in darkness for 16 hours. The reaction mixture is filtered and rotary evaporated to yield a dark oil, which is purified by a silica gel plug as mentioned in 1-methyl-3-hydroxy-2(1H)-pyridinone to give the 3-benzyloxy-4-benzyloxycarbonyl-1-methyl-2(1H)-pyridinone as a pale yellow, thick oil. It is mixed with methanol (50 mL) and a 6 M NaOH solution (10 mL). The mixture is stirred at room temperature for 4 hours, then evaporated to dryness. The residue is dissolved in water (100 mL), and acidified with 6 M HCl solution to pH 2 to give the title compound (9.3 g 88.7%), as a white crystalline product, m.p. 152-153° C. ^{1}H NMR (250 MHz, $CDCl_3$): δ 3.616 (s, 3H), 5.611 (s, 2H), 6.695 (d, 1H, J=7.13), 7.152 (d, 1H, J=7.16), 7.35-7.48 (m, 5H). Anal. for $C_{14}H_{13}NO_4 \cdot 0.2\ H_2O$ (262.87), Calcd. (found): C, 63.97 (64.05); H, 5.14 (5.14); N, 5.33 (5.18).

EXAMPLE 2: Preparation of 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-pyridinone (Formula 24, R_1=methyl)

To a solution of 3-benzyloxy-4-carboxy-1-methyl-2(1H)-pyridinone (1.05 g, 4 mmol), 2-mercaptothiazoline (0.50 g, 4.2 mmol) and a catalytic amount of 4-dimethyl-aminopyridine (DMAP) in dry methylene chloride (50 mL), N,N'-dicyclohexylcarbodiimide (DCC) (0.86 g, 4.2 mmol) is added. After stirring for 4 hours, the

dicyclohexylurea (DCU) solids are removed by filtration, the yellow filtrate is rotary evaporated to give a yellow solid. Crystallization from isopropanol-methylene chloride gives the title compound (1.16 g, 80.4%) as bright yellow crystalline plates, m.p. 149-150° C. ^{1}H NMR (250 MHz, $CDCl_3$) δ 2.867 (t, 2H, J=7.32), 3.594 (s, 3H), 4.313 (t, 2H, J=7.33), 5.301 (s, 2H), 6.107 (d, 1H, J=6.99), 7.126 (d, 1H, J=7.00), 7.31-7.45 (m, 5H). Anal for $C_{17}H_{16}N_2O_3S_2$ Calcd. (found): C, 56.64 (56.36); H, 4.47 (4.47); N, 7.73 (7.73); S, 17.78 (17.41).

EXAMPLE 3: Preparation of 3-hydroxy-1-methyl-4(1-propylcarbamoyl)-2(1H)-pyridinone (Formula 9C, R_1=methyl, R=*n*-propyl, R'=H)

(1) 3-Benzyloxy-1-methyl-4(1-propylcarbamoyl)-2(1H)-pyridinone (Formula 9B, R_1=methyl, R=*n*-propyl, R'=H)

To a solution of 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-pyridinone (720 mg, 2 mmol) in dry methylene chloride (40 mL) is added n-propylamine (0.18 mL, 2.2 mmol) while stirring. The disappearance of the yellow color indicates the end of the amidation reaction. The reaction mixture is concentrated and loaded on a flash silica gel column. Elution with 2-6% methanol in methylene chloride allows the isolation of benzyl protected title compound (522 mg, 87%) as a colorless thick oil. ^{1}H NMR (250 MHz, $CDCl_3$): δ 0.794 (t, 3H, J=7.40), 1.333 (q, 2H, J=7.23), 3.184 (q, 2H, J=7.0), 3.605 (s, 3H), 5.383 (s, 2H), 6.816 (d, 1H, J=7.24), 7.123 (d, 1H, J=7.21), 7.30-7.50 (m, 5H), 7.92 (s, br, 1H).

(2) 3-Hydroxy-1-methyl-4(1-propylcarbamoyl)-2(1H)-pyridinone (Formula 9C, R_1=methyl, R=*n*-propyl, R'=H)

3-Benzyloxy-1-methyl-4(1-propylcarbamoyl)-2(1H)-pyridinone (301 mg, 1 mmol) and 5% Pd/C catalyst (30 mg) are mixed with ethanol (15 mL), the mixture is stirred under hydrogen (1 atm) at room temperature for three hours. After filtration, the filtrate is rotary

evaporated to give a pale pink solid. Crystallization from ethyl acetate gives the titled compound (180 mg, 86%) as a colorless crystalline product, m.p. 163.5-165° C. ^{1}H NMR (250 MHz, DMSO-d_6): δ 0.883 (t, 3H, J=7.41), 1.524 (q, 2H, J=7.30), 3.234 (q, 2H,J=6.57), 3.469 (s, 3H), 6.524 (d, 1H, J=7.43), 7.185 (d, 1H, J=7.42), 8.467 (s,br, 1H). MS (+FAB,TG/G): 211.1 (MH^+, 100%). Anal. for $C_{10}H_{13}N_2O_3$ (209.228), Calcd. (found): C, 57.40 (57.44); H, 6.26 (6.63); N 13.39 (13.25).

EXAMPLE 4: Preparation of 1,3-bis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamido]propane (3-LI-Me-3,2-HOPO, Formula 10, R_1=methyl, m=3)

To a solution of 3-hydroxy-4-benzyloxycarbonyl-1-methyl-2(1H)-pyridinone (1.1 g, 4.2 mmol), 2-mercaptothiazoline (0.52 g, 4.4 mmol), and a catalytic amount of DMAP in dry methylene chloride (50 mL), DCC (0.90 g, 4.4 mmol) is added. The resulting yellow mixture is stirred in darkness for four hours, and 1,3-propanediamine (0.15 g, 2 mmol) is added neatly. The mixture is stirred overnight, and filtered to remove any DCU solids, the filtrate is rotary evaporated and loaded onto a flash silica column. Elution with 2-6% methanol in methylene chloride allows the separation of the benzyl-protected precursor (0.98 g) as a pale yellow thick oil. It is dissolved in glacial acetic acid (20 mL) and hydrogenated by using 10% Pd on charcoal as a catalyst. Filtration followed by rotary evaporation gives a pale brown residue which is recrystallized from methanol to give the title compound (555 mg , 73.3%) as a beige powder, m.p. 268-271° C (dec). ^{1}H NMR (300 MHz, DMSO-d_6): δ 1.757 (t, 2H), 3.327 (q, 4H), 3.469 (s, 6H), 6.503 (d, 2H, J=7.24), 7.193 (d, 2H, J=7.28), 8.483 (s,br, 2H), 11.7 (s, br, 2H). MS (+FAB, NBA): 377.2 (MH^+, 17%), 399.2 (MNa^+, 11%). Anal. for $C_{17}H_{20}N_4O_6$ (376.375), Calcd. (found): C, 54.25 (54.17); H, 5.35 (5.49); N, 14.88 (14.59).

EXAMPLE 5: Preparation of 1,4-bis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamido]butane (4-LI-Me-3,2-HOPO, Formula 10, R_1=methyl, m=4)

This compound is prepared by the procedure of example 4, except 1,4-butanediamine (160 mg, 1.8 mmol) is used instead of 1,3-propanediamine. Separation and purification of the benzyl-protected precursor are performed as described above, the pure precursor is recrystallized from methanol as a white crystalline solid, m.p. 189-190° C. It is deprotected by catalytic hydrogenation as described above. The title compound is recrystallized from methanol to give a beige solid product (462 mg, 68.7%), m.p. 265° C. (dec). ^{1}H NMR (300 MHz, DMSO-d_6): δ 1.541 (s, br, 2H), 3.308 (s, br, 4H), 3.463(s, 6H), 6.515 (d, 2H, J=7.31), 7.187 (d, 2H, J=7.27), 8.483 (t, br, 2H, J=5.34). MS (+FAB, NBA): 391.3 (MH^+, 100%), 413.1 (MNa^+, 25%). Anal. for $C_{18}H_{22}N_4O_6 \cdot 0.5\ H_2O$ (399.41), Calcd. (found): C, 54.13 (54.67); H, 5.80 (5.91); N, 14.02 (13.58).

EXAMPLE 6: Preparation of 1,5-bis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamido]pentane (5-LI-Me-3,2-HOPO, Formula 10, R_1=methyl, m=5)

This compound is prepared by the procedure of example 4, except 1,5-pentanediamine (0.21 g, 2mmol) is used instead of 1,3-propanediamine. Separation and purification of the benzyl-protected precursor are performed as described above, the pure precursor is separated as a pale yellow oil. It is deprotected by catalytic hydrogenation as described above. The deprotected product is recrystallized from methanol to give the title compound (530 mg, 65.7%) as white scale-like micro crystalline product. m.p. 225-6° C (dec). ^{1}H NMR (300 MHz, DMSO-d_6): δ 1.32 (m, 2H), 1.527 (qin, 4H, J=7.17), 3.276 (q, 4H, J=6.49), 3.464 (s, 6H), 6.509 (d, 2H, J=7.33), 7.183 (d, 2H, J=7.34), 8.459 (t, br, 2H, J=5.52). MS (+FAB, NBA): 405 (MH^+, 100%), 427.1(MNa^+, 25%). Anal. for $C_{19}H_{24}N_4O_6 \cdot 0.56H_2O$ (415.24), Calcd. (found): C, 54.96 (54.89); H, 6.12 (5.99); N, 13.45 (13.27).

EXAMPLE 7: Preparation of 1,6-bis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamido]hexane (6-LI-Me-3,2-HOPO, Formula 10, R_1=methyl, m=6)

This compound is prepared by the procedure of example 4, except 1,6-hexanediamine (220 mg, 1.9 mmol) is used instead of 1,3-propanediamine. Separation and purification of the benzyl-protected precursor are performed as described above, the pure precursor is recrystallized from methanol as a white crystalline solid, m.p. 179-180° C. It is deprotected by catalytic hydrogenation as described above. The title compound is recrystallized from methanol to give a white solid product (530 mg, 73.3%), m.p. 240-1° C. (dec). ^{1}H NMR (300 MHz, DMSO-d_6): δ 1.32 (s,br, 4H), 1.501 (t, br, 4H, J= 6.62), 3.258 (q, 4H, J=6.55), 3.452 (s, 6H), 6.502 (d, 2H, J=7.22), 7.183 (d, 2H, J=7.34), 8.455 (t, br, 2H, J=5.36), 11.8 (s, br). MS (+FAB, NBA): 419.2 (MH^+, 10%), 441.2 (MNa^+, 29%), 463.2 (M + Na^+ - H^+, 15%). Anal. for $C_{20}H_{26}N_4O_6 \cdot 0.25\ H_2O$ (422.96), Calcd. (found): C, 56.79 (57.03); H, 6.31 (6.41)); N, 13.24 (12.95).

EXAMPLE 8: Preparation of 1,5-bis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamido]-3-oxypentane (5-LI-O-Me-3,2-HOPO, Formula 11, X=O, m=n=2)

This compound is prepared by the procedure of example 4, except 2,2'-oxybis(ethylamine) dihydrochloride (0.25 g, 1.4 mmol) is used instead of 1,3-propanediamine. Separation and purification of the benzyl-protected precursor are performed as described above, the pure precursor is separated as a pale yellow oil. It is deprotected by catalytic hydrogenation as described above. The title compound is recrystallized from methanol to give a white solid product (510 mg, 89%), m.p. 205° C. (dec). ^{1}H NMR (300 MHz, DMSO-d_6): δ 3.327 (t, 4H), 3.404 (s, 6H), 3.488(t, 4H, J=5.32), 6.452 (d, 2H, J=7.33), 7.107 (d, 2H, J=7.31), 8.483 (s,br, 2H). MS (+FAB, NBA): 407.2 (MH^+, 100%), 429.2 (MNa^+, 72%). Anal. for $C_{18}H_{22}N_4O_7$ (408.20), Calcd. (found): C, 53.19 (53.01); H, 5.48 (5.50); N, 13.72 (13.62).

EXAMPLE 9: Preparation of N,N,N,-tris[(3-benzyloxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamidoethyl]-amine (TREN-Me-3,2-HOPO, Formula 12, m=1)

To a solution of 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-pyridinone (Formula 24, 1.44 g, 4 mmol) in methylene chloride (50 mL), freshly distilled tris(2-aminoethyl)amine (TREN) (0.18 g, 1.2 mmol) is added, the mixture is stirred overnight and then rotary evaporated and loaded onto a flash silica column. Elution with 2-7% methanol in methylene chloride allows for isolation of the pure benzyl-protected precursor as a pale yellow oil. It is dissolved in glacial acetic acid (10 mL) and hydrogenated by using 10% Pd on charcoal as catalyst. Filtration followed by rotary evaporation gives a pale brown residue which is recrystallized from water to give the title compound (486 mg , 67.1%) as a pale yellow crystalline solid, m.p. 130-2° C (dec). ^{1}H NMR (250 MHz, DMSO-d_6): δ 2.296 (t, 6H, J=5.97), 3.072 (q, 6H, J=5.82), 3.449 (s, 9H, NCH_3), 6.458 (d, 3H, J=7.24), 7.122 (d, 3H, J=7.27), 8.46 (t, br, 3H, J=5.3). ^{1}H NMR (250 MHz, D_2O-NaOD): δ 2.901 (t, 6H, J=6.26), 3.450 (s, 9H), 3.520 (t, 6H, J=6.24), 6.568 (d, 3H, J=7.29), 6.609 (d, 3H, J=7.21). MS (+FAB, NBA): 600.3 (MH^+). Anal. for $C_{27}H_{33}N_7O_9 \cdot 1.5\ H_2O$ (626.634) Calcd.(found): C, 51.75 (51.84)); H 5.79 (5.54); N 15.64 (15.59).

EXAMPLE 10: Preparation of N,N,N,-tris[(3-benzyloxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamidopropyl]-amine (TRPN-Me-3,2-HOPO, Formula 12, m=2)

This compound is prepared by the procedure of TREN-Me-3,2-HOPO, except tris(3-aminopropyl)amine (TRPN) (0.16 g, 1.1 mmol) is used instead of TREN. Separation and purification of the benzyl-protected precursor are performed as described in example 9. The title compound (392 mg, 56.6%) is obtained by catalytic hydrogenation deprotection followed by precipitation from methanol/ether mixture and collected by filtration as a pale, greenish-yellow solid, m.p. 165° C (dec) ^{1}H NMR (250 MHz, DMSO-d_6): δ 1,710 (s, br 6H), 2.660 (s,br, 6H), 3.302 (s,br, 6H), 3.429(s, 9H), 6.485 (d, 3H, J=7.30), 7.065 (d, 3H,

J=7.30), 8.80 (s br, 3H). ^{1}H NMR (250 MHz, D_2O-NaOD): δ 1.756 (s, br 6H), 2.592 (s,br, 6H), 3.330 (s,br, 6H), 3.374 (s, 9H), 6.516 (d, 3H, J=7.27), 6.617 (d, 3H, J=7.17). MS (+FAB, TG/G): 642.2 (MH^+, 85%). Anal. for $C_{30}H_{39}N_7O_9 \cdot H_2O$ (659.707), Calcd.(found): C, 54.62 (54.40); H, 6.26 (6.27); N, 14.86 (14.82).

EXAMPLE 11: Preparation of N,N,N,-tris[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamidoethyl]-amine (ME-Me-3,2-HOPO, Formula 13)

To a solution of 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-pyridinone (Formula 24, 400 mg, 1.1 mmol) in methanol (10 mL), a solution of mesitylenetriamine trihydrochloride (82 mg, 0.3 mmol) in pyridine/water (4:1, 10 mL) is added, the mixture is stirred overnight and rotary evaporated to dryness. The residue is dissolved in methylene chloride and loaded onto a flash silica column. Elution with 2-8% methanol in methylene chloride allows for isolation of the pure benzyl-protected precursor as a pale yellow oil, which solidifies upon standing. The title compound (118 mg, 58.3%) is obtained by catalytic hydrogenation deprotection of the precursor followed by recrystallization from methanol as a white solid, m.p. 168-70° C (dec). ^{1}H NMR (300 MHz, DMSO-*d6*): δ 3.470 (s, 9H), 4.463 (d, 6H, J=5.54), 6.495 (d, 3H, J=7.26), 7.147 (s, 3H), 7.159 (d, 3H, J=7.64), 8.913 (t, 3H, J=5.75). MS (+FAB, NBA): 619.2 (MH^+, 100%), 641.2 (MNa^+, 20%). Anal. for $C_{30}H_{30}N_6O_9 \cdot 1.9\ H_2O$ (652.84), Calcd.(found): C, 55.19 (55.31); H, 5.19 (5.19); N, 12.87 (12.62).

EXAMPLE 12: Preparation of N,N,N',N'-tetrakis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamido-ethyl]-ethylenediamine (H(2,2)-Me-3,2-HOPO, Formula 14, m=n=2)

To a solution of 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-pyridinone (Formula 24, 1.44 g, 4 mmol) in methylene chloride (50 mL), N,N,N',N'-tetrakis(2-aminoethyl)ethylenediamine (PENTEN) (258 mg, 0.9 mmol) is added. After

stirring for four hours, the mixture is filtered and evaporated to dryness. The residue is loaded onto a flash silica column. Elution with 3-8% methanol in methylene chloride allows for isolation of the pure benzyl-protected precursor as a pale yellow oil. It is dissolved in glacial acetic acid (20 mL), 20% $Pd(OH)_2$ on charcoal catalyst is added and the mixture is hydrogenated under 400 psi at room temperature overnight. Filtration followed by rotary evaporation gives a pale brown residue which is recrystallized from methanol to give the title compound (397 mg , 52.9%) as a white powder, m.p. 270° C (dec). ^{1}H NMR (250 MHz, DMSO-d_6): δ 2.663 (s,br, 12H), 3.35 (m,br, 8H), 3.436 (s, 12H), 6.465 (d, 4H, J=7.26), 7.093 (d, 4H, J=7.35H), 8.5 (s, br, 4H). MS (+FAB, NBA): 837.3 (MH^+, 100%). Anal. for $C_{38}H_{48}N_{10}O_{12}\cdot H_2O$ (854.884), Calcd.(found): C, 53.39 (53.29); H, 5.89 (5.71); N 16.38 (16.10).

EXAMPLE 13: Preparation of N,N,N',N'-tetrakis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamido-ethyl]-propylenediamine (H(3,2)-N-Me-3,2-HOPO, Formula 14, m=3, n=2)

This compound is prepared by the procedure of H(2,2)-Me-3,2-HOPO, except N,N,N',N'-tetrakis(2-aminoethyl)-propylenediamine (H(3,2)-amine) (76 mg, 0.25 mmol) is used instead of PENTEN. Separation and purification of the benzyl-protected precursor are performed as described in example 12. The title compound (110 mg, 51.5%) is obtained by catalytic hydrogenation deprotection of the precursor followed by recrystallization from methanol as a greenish pale yellow solid, m.p. 141° C (dec). ^{1}H NMR (300 MHz, DMSO-d_6): δ 1.639 (s,br, 2H), 2.644 (s,br, 4H), 2.724 (s, br, 8H), 3.400 (s, br, 8H), 3.424 (s, 12H), 6.448 (d, 4H, J=7.19), 7.040 (d, 4H, J=7.23), 8.778 (s,br, 4H). MS(+FAB, NBA): 851.3 (MH^+, 45%). Anal. for $C_{39}H_{50}N_{10}O_{12}\cdot 1.2H_2O$ (875.52), Calcd.(found): C, 53.69 (53.70); H, 6.05 (5.98); N, 16.05 (16.09).

EXAMPLE 14: Preparation of N,N,N',N'-tetrakis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamido-ethyl]-butylenediamine (H(4,2)-Me-3,2-HOPO, Formula 14, m=4, n=2)

This compound is prepared by the procedure of H(2,2)-Me-3,2-HOPO, except N,N,N',N'-tetrakis(2-aminoethyl)-butylenediamine (H(4,2)-amine) (80 mg, 0.25 mmol) is used instead of PENTEN. Separation and purification of the benzyl-protected precursor are performed as described in example 12. The title compound (125 mg, 58.3%) is obtained by catalytic hydrogenation deprotection followed by recrystallization from methanol as a pale yellow solid, m.p. 124° C (dec). ^{1}H NMR (300 MHz, DMSO-d_6): δ 1.656 (s, br, 2H), 2.719 (s, br, 4H), 2.844 (s,br, 8H), 3.411 (s, br, 8H), 3.450 (s, 12H), 6.403 (d, 4H, J=7.19), 6.969 (d, 4H, J=7.32), 8.811 (s, br, 4H). MS (+FAB, NBA): 865.4 (MH^+, 66%). Anal. for $C_{40}H_{52}N_{10}O_{12} \cdot 2.2H_2O$ (904.56), Calcd.(found): C, 53.06 (53.11); H, 6.28 (6.28); N, 15.47 (15.48).

EXAMPLE 15: Preparation of DFO-1-Me-3,2-HOPO (Formula 17)

(1) Fe(III)-Bn-DFO-1-Me-3,2-HOPO Complex

The mesylate salt of DFO (Desfera, 2.63 g, 4 mmol) and $FeCl_3 \cdot 6\ H_2O$ (1.08 g, 4 mmol) are dissolved in methanol (120 mL) in a 250 mL round flask. To this purple-red solution, KOH solution (1.018 N KOH in methanol (Aldrich), 11.7 mL) is added slowly, while stirring. To the above red Fe(III)-DFO complex (free amine species) solution, a solution of 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-pyridinone (Formula 24, 1.44 g, 4 mmol) in methanol (50 mL) is added slowly, while stirring and the mixture is then stirred overnight. TLC on silica reveals the formation of benzyl protected Fe(III)-1-Me-3,2-HOPO-DFO complex. The red mixture is evaporated to dryness, then loaded on a flash silica column and gradient eluted with 4-20% methanol in methylene chloride. The main red fraction which shows only one spot on TLC (silica) plate is collected and evaporated to dryness, yielding 2.73 g (3.08 mmol, 77.2% based on DFO) of

Fe(III)-Bn-DFO-1-Me-3,2-HOPO Complex. Anal for $C_{39}H_{56}N_7O_{11}Fe \cdot 2\ H_2O$ (890.805), Calcd. (found): C, 52.58 (52.99); H, 6.79 (7.25); N, 11.00 (11.19); Fe, 6.26 (5.97).

(2) Bn-DFO-1-Me-3,2-HOPO

The above Fe(III)-Bn-DFO-1-Me-3,2-HOPO Complex (2.56 g, 3.0 mmol) is dissolved in a minimum amount of water and the pH is adjusted to above 13 with a 12 M NaOH solution. The turbid solution is then filtered to remove the brown $Fe(OH)_3$ precipitate. The slight yellow filtrate is acidified with 6 M HCl, at which point the protected DFO-Me-3,2-HOPO separates as very thick pale yellow oily material. After cooling, the oily product is solidified, it is triturated with the mother liquor and then filtered. The title compound (1.24 g, 51.7%) is obtained after washing with cold water, methanol and drying as a white solid product, m.p. 110-2° C. ^{1}H NMR (300 MHz, DMSO-d_6): δ 1.2-1.5 (m, 18H), 1.967 (s, 3H), 2.276 (t, J=7.04, 4H), 2.586 (t, J=6.83, 4H), 3.007 (q, J=6.14, 2H), 3.456 (t, J=6.94, 6H), 5.203 (s, 2H), 6.262 (d, 1H, J=7.02), 7.3-7.5 (m, 5H), 7.528 (d, 1H, J=7.03), 7.807 (t, br, 2H, J=5.04), 8.220 (t, br, J=5.41), 9.6 (s, br, 3H). MS (+FAB, NBA): m/e 802.4 (MH^+, 100%). Anal. for $C_{39}H_{59}N_7O_{11} \cdot H_2O$ (819.966), Calcd. (found): C, 57.13 (57.37); H, 7.50(7.64); N, 11.96 (11.78).

(3) DFO-Me-3,2-HOPO (Formula 17)

Bn-DFO-Me-3,2-HOPO (0.82 g, 1 mmol) is suspended in methylene chloride (20 mL) in a schlenk flask with a teflon stopcock. Under a flow of argon, the suspension is cooled to 0° C before boron tribromide (1.9 mL, 20 mmol) is injected. The yellow slurry is stirred at room temperature for 72 hours before pumping off the excess BBr_3 and CH_2Cl_2. The remaining pale yellow solid is suspended in cold water. The raw product is collected by filtration, and then dissolved in a 1 M NaOH solution. The solution is then acidified to pH 3 and the resultant precipitate is filtered off and dried to give the title compound (0.37 g, 53%) as a white solid, m.p. 166-8° C (dec). ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.20-1.52

(m, 18H), 1.962 (s, 3H), 2.261 (t, 4H, J = 7.18), 2.571 (t, 4H, J = 7.14), 2.993 (q, 4H, J = 6.32), 3.251 (q, 2H, J = 6.48), 3.450 (t, 6H, J = 7.34), 3.458 (s, 3H), 6.514 (d, 1H, J = 7.24), 7.182 (d, 1H, J = 7.30), 7.778 (t, br, 2H, J = 5.17), 8.484 (t, br, 1H, J = 5.02), 9.617 (s, 2H), 9.660 (s, 1H). MS (+FAB, NBA): 712.4(MH^+, 85%), 734.4 (MNa^+, 82%), 696.4 (60%). Anal for $C_{32}H_{53}N_7O_{11}$ (711.824), Calcd. (found): 53.99 (54.19), 7.50 (7.53), 13.77 (13.48).

EXAMPLE 16: Preparation of TREN-bis-Me-3,2-HOPO-bis-acetic acid (Formula 15)

(1) N,N-Bis[(3-benzyloxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamido-ethyl-N-(2-aminoethyl)amine (Bn-TREN-Bis-Me-3,2-HOPO, Formula 16, Z=$CH_2CH_2NH_2$)

To a solution of 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-pyridinone (Formula 24, 3.2 g, 8.8 mmol) in CH_2Cl_2 (150 mL), a solution of TREN (0.63 g, 4.4 mmol) in 150 mL CH_2Cl_2 is added drop by drop over 16 hours. The reaction mixture is concentrated, loaded on a flash silica gel column (ϕ 40 x 80 mm), and eluted with 4% methanol in methylene chloride to separate 2-mercaptothiazoline and other byproducts. The title compound remains on the top of the column and is separated by further gradient elution with 4-6% CH_3OH + 0.4% Triethylamine. The appropriate fractions are collected and evaporated to give 1.98 g (71%) of a white solid. This is a very useful intermediate to synthesize various mixed 3,2-HOPO chelating agents. ^1H NMR (300 MHz, $CDCl_3$): δ 2.347(m, 6H), 2.484(m, 2H), 3.198 (q, 4H, J=5.97), 3.591(s, 6H), 5.324 (s, 4H), 6.714 (d, 4H, J=7.20), 7.117 (d, 4H, J=7.20), 7.27-7.43 (m, 10H), 7.978 (s br, 2H).

(2) Ethylenediamine-N,N-bis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-carboxamidoethyl]-N',N'-diacetic acid) (TREN-bis-Me-3,2-HOPO-bis-acetate, Formula 15)

N,N-Bis[(3-benzyloxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamido-ethyl-N-(2-aminoethyl)amine (2.0 g, 3.2 mmol), benzyl 2-bromoacetate (2.29 g, 10 mmol) and anhydrous K_2CO_3 (1.5 g, 10 mmol) are combined in dry THF (50 mL). The stirred mixture

is warmed to 60° C overnight under nitrogen. After cooling to room temperature, the reaction mixture is filtered, the filtrate is rotary evaporated and applied to a flash silica gel column. Elution with 0.5-4.0% CH_3OH in CH_2Cl_2 produces a pale yellow thick oil as pure benzyl protected precursor. It is dissolved in glacial acetic acid (20 mL), 20% $Pd(OH)_2$ on charcoal catalyst (200 mg) is added and the mixture hydrogenated under 400 psi at room temperature overnight. Filtration followed by rotary evaporation gives a pale brown residue which is recrystallized from methanol to give the title compound (0.93 g, 53.1%) as a white powder, m.p. 194-6° C (dec). ^1H NMR (500 MHz, D_2O): δ 3.291 (s,br, 4H), 3.367 (s, 6H), 3.38-3.39 (m,br, 2H), 3.40-3.42 (m,br, 2H), 3.542 (s,br, 4H), 3.791 (s, NH), 6.351 (d, 2H, J=4.35), 6.839 (d, 2H, J=4.34). MS (+FAB, TG/G): 565.2(MH^+, 100%), 587.2 (MNa^+, 20%). Anal for $C_{24}H_{32}N_6O_{10}\cdot 1.2\ H_2O$ (582.824), Calcd. (found): C,49.17(49.68); H, 5.91 (6.15); N, 14.33 (13.98).

EXAMPLE 17: Preparation of Thorium (IV) Complex with 3-Hydroxy-1-methyl-4-(1-propylcarbamoyl)-2(1H)-pyridinone

To a solution of 1-Me-3,2-HOPO propylamide (Formula 9B, R=methyl, R'=H, 84 mg, 0.40 mmol) in dry acetonitrile (10 mL), a solution of thorium acetylacetonate (63 mg, 0.1 mmol) in acetonitrile (10 mL) is added while stirring. The clear mixture solution turns turbid after a few minutes, it is refluxed overnight under nitrogen. The resultant precipitate is filtered off and dried to give the title compound (66 mg, 88%) as a beige solid, m.p. 216-8° C. ^1H NMR (300 MHz, DMSO) : δ 0.666(t, 12H, J=7.39), 1.158(q, 8H, J=7.17), 2.956(q, 8H, J=6.47), 3.487 (s, 6H), 6.819 (d, 2H, J=7.03), 6.974 (d, 2H, J=7.19), 9.397(t, 4H, J=5.57). MS (+FAB, TG/G) 1069.7 (ThL_4H^+, 50%), 859.3(ThL_3^+, 100%). Anal for $ThC_{40}H_{52}N_8O_{12}\cdot 2.5H_2O$ (1114.43), Calcd. (found): C, 43.11(43.13); H, 5.15 (4.91); N, 10.05 (9.79).

EXAMPLE 18: Preparation of Ferric Ion Complex with 1,3-Bis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamido]propane

To a suspension of 3-LI-Me-3,2-HOPO (Formula 10, m=3, 245 mg, 0. 65 mmol) in dry methanol (10 mL), 0.65 mL of 1.018 M KOH/methanol (Aldrich) is added to make a clear solution. A solution of ferric acetylacetonate complex (140 mg, 0.4 mmol) in dry methanol (10 mL) is added to the above ligand solution while stirring and results in a deep red color. The solution is evaporated under vacuum to give a black-red powdery solid, which is loaded on a lipophilic sephadex (LH 20) column and eluted with methanol. The deep red band is collected and rotary evaporated to give the title complex (160 mg, 65%) as a powdery red-black solid. MS (+FAB, NBA): 1235.7 (MH^+,100%), shows typical isotope distribution for iron compounds. Anal for $Fe_2C_{51}H_{54}N_{12}O_{18}\cdot H_2O$ (1252.79), Calcd. (found): C, 48.89 (48.66); H, 4.50 (4.71); N, 13.41 (13.23); Fe, 8.91 (8.75).

EXAMPLE 19: Preparation and Crystal Structure of Ferric Ion Complex with N,N,N,-Tris[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamidoethyl]-amine (Fe(III)-TREN-3,2-HOPO complex)

To a solution of TREN-Me-3,2-HOPO (63 mg, 0.10 mmol) in distilled water (20 mL), a solution of $FeCl_3$ (27 mg, 0.1 mmol) in water (5 mL) is added while stirring. The purple-red mixture solution is neutralized with saturated $NaHCO_3$ solution. The complex deposits upon standing overnight. It is filtered out and dried to give the title complex (62 mg, 95%) as black-red crystals. MS (+FAB, NBA): 653.3 (MH^+, 61%), shows an isotopic distribution typical for iron complexes. Anal. for $FeC_{27}H_{30}N_7O_9\cdot H_2O$ (670.45), Calcd. (found): C, 48.37 (48.36); H, 4.81 (5.01); N, 14.62 (14.38).

Crystals of this compound suitable for x-ray diffraction are prepared by vapor diffusion of ether into its wet DMF solution. Its chemical formula is $2FeC_{29}H_{30}N_7O_9 \cdot 2H_2O\cdot C_3H_7NO$. Its crystal structure is shown in Figure 1 and the crystallographic data and parameters for this compound are shown in Table 1. The structure reveals extensive

delocalization and a strong hydrogen bonding between the amide proton and its adjacent HOPO oxygen donor, as shown in Formula 8.

Table 1.

Crystallographic Data and Parameters for $2FeO_9N_7C_{27}H_{30}\cdot 2H_2O\cdot C_3H_7NO$

Formula:	$2FeO_9N_7C_{27}H_{30}\cdot 2H_2O\cdot C_3H_7NO$
Formula Weight(amu)	1487.13
Temperature (° C)	-116
Crystal System	triclinic
Space Group (#)	$P\bar{1}$ (#2)
Cell Constants[a]	
a (Å)	12.774(3)
b (Å)	12.838(4)
c (Å)	20.740(7)
α (°)	91.33(3)
β (°)	92.92(2)
γ (°)	102.72(3)
Z	4
V(Å^3)	3311(3)
Abs. Coeff., μ_{calc} (cm^{-1})	5.46
d_{calc}	1.49
F(000)	1540
Crystal dimensions (mm)	0.65 x 0.50 x 0.20 mm
Radiation	Mo-Ka (l=0.71073)
Diffractometer	Enraf-Nonius CAD-4
h, k, l range collected	0→13,-13→+13,-22→+22
2θ range	3° - 45°
Scan Type	Omega-2Theta
Scan speed (θ, °/min.)	5.49°/min
Reflections collected	8625
Unique reflections:	8625
Reflections with ($F_o^2 > 3*\sigma(F_o^2)$)	6168
Number of parameters	901
Data/parameter ratio	6.8
$R=[\Sigma\|\Delta F\|/\Sigma\|F_o\|]$	0.081
$R_w=[\Sigma w(\Delta F)^2/\Sigma wF_o^2]$	0.103
GOF	2.994
Final Diff. ρ_{max} (e$^-$/ Å^3)	+1.3[b]

[a]Unit cell parameters and their esd's were derived by a least-squares fitting of the setting angles of 24 reflections in the range $9.9° \leq 2\theta \leq 13.9°$.

[b]Located near Fe 2.

EXAMPLE 20: Preparation and Crystal Structure of Gadolinium (III) Ion Complex with N,N,N,-Tris[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamidoethyl]-amine (Gd(III)-TREN-3,2-HOPO complex)

To a solution of TREN-Me-3,2-HOPO (63 mg, 0.10 mmol) in dry methanol (10 mL), a solution of gadolinium nitrate pentahydrate (43 mg, 0.1 mmol) in dry methanol (10 mL) is added while stirring. The clear solution turns turbid after 2 drops of dry pyridine are added. The mixture is refluxed overnight under nitrogen, during which time the complex deposits as a white fluffy precipitate. It is filtered out, rinsed with cold methanol, and dried to give the title complex (66 mg, 88%) as a white solid. MS (+FAB, NBA): 753.3 (MH^+,100%), shows an isotopic distribution typical for gadolinium compounds. Anal. for $GdC_{27}H_{30}N_7O_9 \cdot 1{\cdot}4\ H_2O$ (779.05), Calcd. (found): C, 41.62 (41.70); H, 4.24 (4.26); N, 12.58 (12.28).

This complex is very stable in aqueous solution with a formation constant log β_{110} of 20.3 and a pM value for Gd^{3+} of 19. This is substantially more stable than any of the Gd^{3+} MRI agents in current clinical use.

Crystals of this compound suitable for x-ray diffraction are prepared by vapor diffusion of ether into its wet DMF solution. Its chemical formula is $GdC_{29}H_{30}N_7O_9 \cdot 2H_2O \cdot C_3H_7NO$. Its crystal structure is shown in Figure 2 and the crystallographic data and parameters for this compound are shown in Table 2.

Solution of the structure indicates that the compound consists of molecules containing one gadolinium (III) ion which coordinates with a hexadentate TREN-Me-3,2-HOPO ligand and two water molecules, so that the square antiprism coordination requirement of the gadolinium atom is satisfied by the oxygen atoms of three bidentate hydroxypyridonate moieties and two water molecules. The structure reveals extensive delocalization and a strong hydrogen bonding between the amide proton and its adjacent HOPO oxygen donor, as shown in Formula 8. Because of the large number of coordinated

water molecules, this class of compounds is expected to show good nuclear magnetic relaxation properties as need for magnetic resonance imaging.

Table 2.

Crystallographic Data and Parameters for $GdO_9N_7C_{27}H_{30}\cdot 2H_2O\ C_3H_7NO$

Formula:	$GdO_9N_7C_{27}H_{30}\cdot 2H_2O\cdot C_3H_7NO$
Formula Weight (amu)	862.96
Temperature (° C)	-117
Crystal System	triclinic
Space Group (#)	$P\bar{1}$ (#2)
Cell Constants[a]	
a (Å)	10.791(3)
b (Å)	12.901(4)
c (Å)	13.566(4)
α (°)	85.42(2)
β (°)	67.38(2)
γ (°)	74.58(2)
Z	2
V(Å^3)	1680(1)
Abs. Coeff., μ_{calc} (cm^{-1})	20.54
d_{calc}	1.706
F(000)	874
Crystal dimensions (mm)	0.30 x 0.11 x 0.08 mm
Radiation	Mo-Ka (λ=0.71073)
Diffractometer	Enraf-Nonius CAD-4
h, k, l range collected	0→11, -13→+13, -14→+14
2θ range	1.5 - 22.5
Scan Type	Omega-2Theta
Scan speed (θ, °/min.)	5.49°/min
Reflections collected	4377
Unique reflections:	4377
Reflections with ($F_o^2 > 3*\sigma(F_o^2)$)	3576
Number of parameters	460
Data/parameter ratio	7.8
$R=[\Sigma\|\Delta F\|/\Sigma\|F_o\|]$	0.036
$R_w=[\Sigma w(\Delta F)^2/\Sigma wF_o^2]$	0.039
GOF	1.385
Final Diff. ρ_{max} (e$^-$/ Å^3)	+1.008[b]

[a]Unit cell parameters and their esd's were derived by a least-squares fitting of the setting angles of 24 reflections in the range 23.24°≤2θ≤24.56°.

[b]Located near Gd.

EXAMPLE 21: *In Vivo* Test of Promoting Excretion of $^{238}Pu(IV)$ in Mice by Injected Ligands

The novel chelating agents of the present invention were tested for their effectiveness in promoting excretion of $^{238}Pu(IV)$ in mice by injected ligands as follows. Mice, in groups of five, each received an intravenous injection of 1850 Bq $^{238}Pu(IV)$ in 0.2 mL of citrate buffer. One hour later, 30 μmol/kg of ligand was injected intraperitoneally in 0.5 mL of saline. The mice were killed 24 hours after the Pu injection, frozen, and dissected after partial thawing. The ^{238}Pu in skeleton, soft tissues, and separated excreta was determined by counting the ^{234}U L x-rays. Results of removal of $^{238}Pu(IV)$ from mice by injected ligands are summarized in Table 3, which also includes data for $CaNa_3$-DTPA and other reference ligands and the Pu-injected controls. As illustrated by the data in Table 3, all the novel 3,2-HOPO chelating agents provide effective Pu removal, and the tetradentate ligands such as 5-LI-O-Me-3,2-HOPO, 5-LI-Me-3,2-HOPO and 4-LI-Me-3,2-HOPO are, surprisingly, as effective or more effective than the hexadentate and octadentate chelating agents. While in the case of multidente 1,2-HOPO and catechoylamide chelating agents, octadentates are always better chelating agents than the correspond hexadentates and tetradentates.

Table 3.

Removal of $^{238}Pu(IV)$ from Mice by Injected Ligands Composed of Me-3,2-HOPO

Ligand	*no.of mice*	percent of injected $^{238}Pu \pm SD$ at 24 h[a,b]						
		tissues					excreta	
		skeleton	liver	soft tissue	kidneys	whole body	feces and GI contents	urine 0-24 h
Me-3,2-HOPO Ligands[c]								
5-LI-O-Me-3,2-HOPO	*5*	11 ± 1.6	2.1 ± 0.3[d]	1.6 ± 0.2[d]	0.2	15 ± 2.1[d]	61.7	23.5
5-LI-Me-3,2-HOPO	*10*	10 ± 1.2	3.1 ± 0.8[d]	1.9 ± 0.5	0.3	16 ± 1.9[d]	67.6	17.5

4-LI-Me-3,2-HOPO	*10*	11 ± 1.7	3.7 ± 1.5[d]	1.9 ± 0.5	0.4	17 ± 2.4[d]	63	19.4
TREN-Me-3,2-HOPO	*15*	10 ± 1.1	5.0 ± 2.2[d]	2.5 ± 0.8	0.6	18 ± 2.7[d]	43.3	37
H(2,2)-Me-3,2-HOPO	*10*	11 ± 1.7	3.8 ± 1.1[d]	2.8 ± 1.6	1.3	19 ± 2.9[d]	45.3	36
ME-Me-3,2-HOPO	*5*	12 ± 1.8	6.1 ± 4.9[d]	3.0 ± 2.0	0.9	22 ± 8.5[d]	70.1	33.5
6-LI-Me-3,2-HOPO	*10*	12 ± 1.8	6.5 ± 3.7[d]	3.7 ± 1.8	0.5	23 ± 4.9[d]	62.9	14.4
3-LI-Me-3,2-HOPO	*10*	14 ± 1.9	9.5 ± 4.9[d]	2.6 ± 0.4	0.5	27 ± 5.2	41.6	32
H(3,2)-Me-3,2-HOPO	*5*	10 ± 2.0	14 ± 6.1	2.4 ± 0.3[d]	1.2	28 ± 4.8	52.1	19.5
TREN-bis(Me-3,2-HOPO)-bis acetic acid	*10*	20 ± 1.7	6.6 ± 2.2[d]	2.7 ± 0.8	0.5	30 ± 3.6	34.6	8.7
TRPN-Me-3,2-HOPO	*5*	14 ± 3.2	17 ± 5.0	2.0 ± 1.1	0.7	33 ± 5.3	11.5	55
H(4,2)-Me-3,2-HOPO	*5*	12 ± 2.9	29 ± 6.1	1.9 ± 1.0	1.8	46 ± 8.5	26.8	28
DFO-Me-3,2-HOPO[e]	*10*	17 ± 2.4	13 ± 3.5	19 ± 3.0	3.0	53 ± 3.4	26.4	21
Reference Ligands[c,e]								
DFO-(1,2-HOPO)	*5*	6.0 ± 0.5[d]	5.1 ± 2.2[d]	2.3 ± 0.5[d]	0.1	13 ± 2.9[d]	46.7	9.5
3,4,3-LI(1,2-HOPO)	*5*	7.5 ± 0.7[d]	8.9 ± 1.7[d]	1.6 ± 0.6[d]	0.2	18 ± 1.7[d]	57	23
$CaNa_3$-DTPA	*15*	12 ± 2.3	17 ± 4.0	3.5 ± 1.6	1.1	33 ± 6.6	5.1	61
3,4-LI(1,2-HOPO)	*5*	9.9 ± 3.6	18 ± 4.8	5.8 ± 1.3	0.6	34 ± 9.2	58	7.9
3-LI(1,2-HOPO)	*5*	17 ± 2.8	8.7 ± 1.2[d]	11 ± 0.8	1.4	38 ± 4.4	53.3	8.7
DFO	*10*	20 ± 11	19 ± 13	4.5 ± 1.4	1.8	45 ± 2.5	15.1	38
ME-(1,2-HOPO)	*5*	17 ± 2.5	18 ± 6.3[d]	10 ± 1.8	1.8	47 ± 9.4	43	9.6
Pu-Injected Controls (fed)								
kill at 24 h	*143*	31 ± 7.4	50 ± 7.9[d]	7.8 ± 2.1	1.8	91 ± 6.0	4.4	3.8

[a] $SD=[\Sigma dev^2(n-1)^{-1}]^{1/2}$. No SD is shown for kidneys or excreta, because samples for five-mouse groups were pooled for radioanalysis. Data for each mouse, expressed as % ID, were normalized to 100% material recovery; discrepancies are due to rounding.

[b] Ligands were injected (30 μmol kg^{-1}, ip) at 1 h, and mice were killed at 24 h after iv injection of $^{238}Pu(IV)$ citrate.

[c] Skeleton, liver, and body Pu of ligand-treated groups are significantly less than 24 h Pu-injected controls (t test, $p \leq 0.01$).

[d] Significantly different from mice given $CaNa_3$-DTPA (t test, $p \leq 0.01$).

[e] Reported previously and shown here to facilitate comparisons.

EXAMPLE 22: *In Vivo* Test of Promoting Excretion of $^{238}Pu(IV)$ in Mice by Orally Administered Ligands

The novel chelating agents of the present invention were tested for their effectiveness in promoting excretion of $^{238}Pu(IV)$ by orally administration to mice as

follows. Mice in groups of five, each received an intravenous injection of 1850 Bq $^{238}Pu(IV)$ in 0.2 mL of citrate buffer. Three minutes later, 30 mmol/kg of ligand was given by gavage in 0.5 ml of saline. The mice were killed 24 hours after the $^{238}Pu(IV)$ injection, frozen, and dissected after partial thawing. The $^{238}Pu(IV)$ in skeleton, soft tissues, and separated excreta was determined by counting the ^{234}U L x-rays. Results of removal of $^{238}Pu(IV)$ from mice by orally administered ligands are summarized in Table 4, which also includes data for the reference ligands, and the Pu-injected controls. As illustrated by the data in Table 4, the octadentate and hexadentate chelating agents are superior by oral administration, and the hexadentate ligand TREN-Me-3,2-HOPO is the most effective both (by oral and injection) cases.

Table 4.

Removal of $^{238}Pu(IV)$ from Mice by Orally Administered Ligands Composed of Me-3,2-HOPO

		percent of administered $^{238}Pu \pm SD$ at 24 h[a,b]						
		tissues					excreta	
Ligand	*no.of mice*	skeleton	liver	soft tissue	kidneys	whole body[c]	feces and GI contents	urine 0-24 h
Me-3,2-HOPO Ligands								
H(2,2)-Me-3,2-HOPO	*15*	11 ± 4.6	7.6 ± 6.5	4.0 ± 2.1[c]	0.4	23 ± 11	37.9	39
TREN-Me-3,2-HOPO	*10*	13 ± 5.5	8.5 ± 4.7	1.9 ± 1.2[c]	0.7	25 ± 12	34.1	42
H(3,2)-Me-3,2-HOPO	*5*	14 ± 6.7	13 ± 5.9	4.1 ± 1.9	1.4	33 ± 13	25.4	42
H(4,2)-Me-3,2-HOPO	*5*	15 ± 6.2	19 ± 4.9	1.8 ±0.8	1.3	37 ± 10	10.1	52.4
5-LI-O-Me-3,2-HOPO	*5*	23 ± 5.9	16 ± 4.4	4.0 ± 0.8[c]	0.8	43 ± 10	44.7	12.5
5-LI-Me-3,2-HOPO	*5*	23 ± 11	24 ± 5.3	4.4 ± 2.0	0.8	53 ± 17	27.1	20
4-LI-Me-3,2-HOPO	*5*	15 ± 6.1	34 ± 7.7	3.6 ± 1.5	0.5	54 ± 13	13.6	32.5
DFO-Me-3,2-HOPO	*10*	20 ± 7.6	22 ± 7.7	15 ±4.0	2.4	60 ± 11	17.3	22.4
TRPN-Me-3,2-HOPO	*5*	28 ± 8.0	28 ± 3.1	4.3 ± 1.7[c]	0.7	60 ± 11	35.5	5.4
3-LI-Me-3,2-HOPO	*10*	27 ± 7.7[c]	33 ± 4.4	5.0 ± 1.2	0.8	66 ± 11	7.9	27
TREN-bis(Me-3,2-HOPO)bis acetic acid	*10*	28 ± 5.2[c]	38 ± 2.7[d]	4.1 ± 0.7	0.6	71 ± 5.6	10.0	19.1

6-LI-Me-3,2-HOPO	*10*	25 ± 3.1[c]	44 ± 5.0	6.2 ± 1.1	1.3	76 ± 5.8[c]	9.8	14.2
ME-Me-3,2-HOPO	*5*	34 ± 24.5	40 ± 1.8	7.5 ± 1.7	1.2	82 ± 3.9[c]	6.7	12.4
Reference Ligands[c]								
DFO-(1,2-HOPO)	*5*	12 ± 2.4	11 ± 4.9	1.3 ±0.7	0.1	24 ± 7.7	51.4	25.7
3,4,3-LI(1,2-HOPO)	*5*	33 ± 5.0	22 ± 7.7[d]	3.9 ± 0.8	0.2	60 ± 8.2	12.3	29
$CaNa_3$-DTPA	*5*	35 ± 2.7	45 ± 2.4	4.1 ± 0.7	1.1	85 ± 1.8	5.0	9.5
Pu-Injected Controls (fed)								
kill at 24 h	*20*	39 ± 7.2	43 ± 6.2[d]	6.0 ± 1.5	1.6	90 ± 3.6	4.5	5.4

[a] SD = $[\sum dev^2 (n-1)^{-1}]^{1/2}$. No SD is shown for kidneys or excreta, because samples for five-mouse groups were pooled for radioanalysis. Data for each mouse, expressed as % ID, were normalized to 100% material recovery; discrepancies are due to rounding.

[b] Ligands were given (30 μmole kg^{-1}, by garage) at 3 min, and mice were killed at 24 h after iv injection of $^{238}Pu(IV)$ citrate.

[c] Mean is significantly less than that of 24-h fasted Pu controls (t test, $p \leq 0.01$)

[d] Mean is significantly less than that of mice gavaged with $CaNa_3$-DTPA (t test, $p \leq 0.01$)

EXAMPLE 23: *In Vivo* Test of Promoting Excretion of Am(III), Np(IV), and U(VI) in Mice by Injected TREN-Me-3,2-HOPO

One of the novel chelating agents of the present invention, TREN-Me-3,2-HOPO, was also tested for effectiveness in promoting excretion of ^{241}Am (III), ^{237}Np (V),and ^{232}U (VI) by injection into mice, as follows: Mice, in groups of five, each received an intravenous injection of (a) 1100 Bq of ^{241}Am(III) in 0.2 mL of citrate buffer, (b) 150 Bq of $^{232}UO_2Cl_2$ plus 3.6 mg of $^{235}UO_2Cl_2$ in 0.2 mL of saline, or (c) 200 Bq of $^{237}NpO_2Cl$ (7.5 mg of $^{237}NpO_2Cl$) in 0.2 mL of saline. Three to five minutes later, 30 mmol/kg of TREN-Me-3,2-HOPO was injected intraperitoneally in 0.5 mL of saline. The mice were killed 24 hours after the actinide injection, frozen, and dissected after partial thawing. The skeleton, soft tissues, and separated excreta were radioanalyzed by counting the ^{241}Am gamma rays, or the alpha particles emitted by ^{237}Np or ^{232}U (and its ingrowing daughters). Removal of those actinides from mice by injected TREN-Me-3,2-HOPO is summarized in Table 5, which also includes data for mice similarly treated with $CaNa_3$-DTPA and for actinide-injected controls. As shown by the data in Table 5, TREN-Me-3,2-HOPO reduced the body content of all three actinides to a significantly greater degree than

$CaNa_3$-DTPA. Compared with controls, the Am content of all tissues was greatly reduced, the Np content of the soft tissues was significantly reduced, and more than one-half of the U burden in the kidneys was removed. The structure of Am(III)-TREN-Me-3,2-HOPO is considered to resemble that of the Gd(III) complexes (see example 20). Complexation of the fraction of Np(V) that is reduced *in vivo* to Np(IV) is considered to resemble that of Pu(IV). Complexation of U(VI) is considered to take place through binding to UO_2^{2+}.

Table 5

Removal of ^{241}Am(III), ^{237}Np(V), or $^{232,234,235}U$(VI) from Mice by Injected TREN-Me-3,2-HOPO[a]

	percent of injected actinide ± SD at 24 h[a,b,c]						
	tissues					excreta	
Ligand	skeleton	liver	soft tissue	kidneys	whole body	feces and GI contents	urine 0-24 h
Am(III)							
TREN-Me-3,2-HOPO	8.1 ± 1.6[d]	1.0 ± 0.6[d,e]	1.6 ± 0.6[d]	0.2	11 ± 1.4[d,e]	38	51
$CaNa_3$-DTPA	8.5 ± 0.9[d]	13 ± 1.5[d]	1.9 ± 0.3[d]	0.4	24 ± 1.3[d]	8.0	68
Am controls,kill 24h	27 ± 5.3	50 ± 5.3	5.7 ± 0.7	1.2	84 ± 3.7	2.6	14
Np(V)							
TREN-Me-3,2-HOPO	34 ± 4.5	3.8 ± 5.7[d,e]	3.1 ± 1.1	1.0	42 ± 11[d,e]	17	40
$CaNa_3$-DTPA	40 ± 4.4	14 ± 5.7	3.5 ± 0.9	1.3	58 ± 8.0	1.5	40
Np controls,kill 24 h	37 ± 5.1	1.4 ± 2.3	5.8 ± 2.3	1.7	59 ± 4.1	41[f]	
U(VI)							
TREN-Me-3,2-HOPO	16 ± 2.4	0.6 ± 0.3	1.6 ± 0.3	9.4 ± 6.0[d,e]	27 ± 8.5[d,e]	2.3	70
$CaNa_3$-DTPA	19 ± 3.0	1.0[c]	2.2 ± 0.1	17 ± 2.8	38 ± 0.7	62[f]	
U controls, kill 24 h	17 ± 2.5	1.4[c]	2.8 ± 0.5	19 ± 6.9	40 ± 7.8	60[f]	

[a] Ligands (30 mmol.kg^{-1}) i.p at 3 to 5 min after actinide i.v.; kill at 24 h.
[b] Groups of five mice except: TREN-Me-3,2-HOPO ip at 3 min after 24 h Am, 10; 24 h Am, Np, or U controls, 10. Results are expressed as percent of injected actinide (ID %) normalized to 100% material recovery, discrepancies are due to rounding.

[c] Standard deviation. $SD=[\Sigma dev^2(n-1)^{-1}]^{1/2}$. Kidneys of Am- and Np-injected mice, livers of some U-injected groups, and all excreta were pooled for each five-mouse group.
[d] Significantly less actinide than appropriate controls (t test, $p \leq 0.01$).
[e] Significantly improved actinide reduction than for mice given $CaNa_3$-DTPA in same protocol.
[f] Combined excreta.

EXAMPLE 24: *In Vivo* Toxicity Test of Injected Ligands in Mice

The test of acute toxicity of these novel ligands was carried out as follows. Groups of five mice were each given a single i.p. injection of 100 mmol/kg of ligand a day for 10 days or given two i.p. injection of 500 mmol/kg in 8 hours. The ligand was dissolved in 0.5 to 1.0 ml of saline at pH 7 to 8. After a period of observation, the mice were killed, selected tissues were removed and fixed for histopathological examination, and unusual findings at autopsy were recorded. Results of the initial test of toxicity of the ligands tested are summarized in Table 6. The highly effective ligands, such as TREN-Me-3,2-HOPO, 5-LI-Me-3,2-HOPO and 5-LI-O-Me-3,2-HOPO proved to be of low toxicity, even at the relatively high dosage of 2x500 µmol/kg in 8 hours.

Table 6.

Initial Evaluation of Acute Toxicity in Mice of Ligands Composed of 1-Me-3,2-HOPO[a]

protocol and ligand	study length (d)[b]	no of mice	no. of survivors [c]	percent control mean ± SD[d] body weight	kidney weight	plasma urea N
I. 100 µmol·kg^{-1} x 10 daily						
TREN-Me-3,2-HOPO	11	5	5	102 ± 1	-	112 ± 10
TERN-Me-3,2-HOPO	21	5	5	106 ± 4	-	120 ± 9
H(2,2)-Me-3,2-HOPO	11	5	5	92 ± 6	-	223 ± 28
H(2,2)-Me-3,2-HOPO	21	5	5	87 ± 9	-	225 ± 188
5-LI-Me-3,2-HOPO	11	5	5	102 ± 5	109 ± 14	89 ± 1
5-LI-Me-3,2-HOPO	21	5	5	102 ± 5	100 ± 4	101 ± 2

5-LI-O-Me-3,2-HOPO	11	5	5	103 ± 5	100 ± 19	83 ± 5
5-LI-O-Me-3,2-HOPO	21	5	5	101 ± 5	111 ± 5	86 ± 18
IA. 100 μmol·kg^{-1} x 2 daily						
3-LI-Me-3,2-HOPO	6	10	0	89 ± 4	222 ± 29	≥1800
6-LI-Me-3,2-HOPO	3	5	5	83 ± 3	132 ± 11	343 ± 140
6-LI-Me-3,2-HOPO	11	5	3	101 ± 5	112 ± 13	92 ± 6
IB. 100 μmol·kg^{-1}						
4-LI-(Me-3,2-HOPO	5	3	0	85 ± 8	190 ± 63	>2000
II. 500 μmol·kg^{-1} x 2 in 8 h						
TREN-(Me-3,2-HOPO	8	19[e]	19	101 ± 4	-	119 ± 15
H(2,2)-Me-3,2-HOPO)	8	10	3	94 ± 6	-	169 ± 10
5-LI-Me-3,2-HOPO	11	5	5	99 ± 3	109 ± 9	98 ± 18
5-LI-O-Me-3,2-HOPO	11	10	10	100 ± 2	108 ± 10	77 ± 10

[a] Control data: Body weight ratio, (W(t)/W(o)) 8 to 11d, 1.01 ± 0.03 (15); 21 d, 1.06 ± 0.06 (10). Kidney weight (g), 2 x left kidney, 0.44 ± 0.04 (25). Plasma urea N (mg dL^{-1}) (15 groups of five) range 11.4 ± 1.2 to 22.2 ± 2.5, median 20.2 ± 2.3, grand mean 15 groups 18.5 ± 3.2.

[b] Days after first ligand injection

[c] Number of survivors and of autopsied mice contributing numerical data, with two exceptions. In the case of 3-LI-Me-3.2-HOPO data are shown for two moribund mice autopsied on d 3; all mice were dead by d 3. In all cases mice found dead were not autopsied.

[d] Underlined means significantly different from control means, t test, $p < 0.01$.

[e] Two replicate 10-mouse groups, one mouse lost in an injection accident.

CLAIMS

1. A hydroxypyridinone chelating agent selected from the group consisting of:



,


or


wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; R is a backbone linking group; R' is selected from the group consisting of hydrogen, C_{1-8} aliphatic hydrocarbon groups, aryl groups and C_{1-8} aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R_1 and R_2 are separately selected from hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group.

2. A hydroxypyridinone chelating agent according to claim 1, wherein said linking group is a molecular backbone linking group; and said molecular backbone linking group is of linear, branched linear, multipodal or macrocyclic topology.

3. A hydroxypyridinone chelating agent according to claim 2, wherein said molecular backbone linking group additionally bears at least one chelating functional unit selected from the group consisting of:





or mixtures thereof, wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; an amide free valency is the point of attachment to said molecular backbone linking group; R' is selected from the group consisting of hydrogen, C_{1-8} aliphatic hydrocarbon groups, aryl groups and C_{1-8} aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R_1 and R_2 are separately selected from hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group.

4. A hydroxypyridinone chelating agent according to claim 3, wherein said molecular backbone linking group additionally bears at least one chelating functional unit selected from the group consisting of: amino acetic acid, catechols, 2,3-dihydroxyterephthalamides, and hydroxamic acids.

5. A hydroxypyridinone chelating agent according to claim 3, wherein all of said chelating functional units are:



6. A hydroxypyridinone chelating agent according to claim 1, wherein said backbone linking group is a polymeric backbone linking group.

7. A hydroxypyridinone chelating agent according to claim 6, wherein said polymeric backbone linking group additionally bears a combination of at least one type of chelating functional unit selected from the group consisting of:



,


,


,

or mixtures thereof, wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; an amide free valency is a point of attachment to said polymeric backbone linking group; R' is selected from the group consisting of hydrogen, C_{1-8} aliphatic hydrocarbon groups, aryl groups and C_{1-8} aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R_1 and R_2 are separately selected from hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group.

8. A chelating agent according to claim 7, wherein said polymeric backbone linking group additionally bears chelating functional units selected from the group consisting of: amino acetic acid, catechols, 2,3-dihydroxyterephthalamides, and hydroxamic acids.

9. The chelating agent 5-LI-O-Me-3,2-HOPO.

10. The chelating agent 5-LI-Me-3,2-HOPO.

11. The chelating agent TREN-Me-3,2-HOPO.

12. The chelating agent H(2,2)-Me-3,2-HOPO.

13. A pharmaceutical composition comprising the chelating agent selected from the group consisting of:



,


or


wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; R is a molecular backbone linking group; R' is selected from the group consisting of hydrogen, C_{1-8} aliphatic hydrocarbon groups, aryl groups and C_{1-8} aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R_1 and R_2 are separately selected from hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group, together with a physiologically acceptable diluent or carrier.

14. A pharmaceutical composition according to claim 13 which further comprises a solid carrier and is in a form suitable for oral administration.

15. A pharmaceutical composition according to claim 14, wherein said molecular backbone linking group is of linear, branched linear, multipodal or macrocyclic topology.

16. A pharmaceutical composition according to claim 15, wherein said molecular backbone linking group additionally bears at least one chelating functional unit selected from the group consisting of:



or mixtures thereof, wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; an amide free valency is the point of attachment to said molecular backbone linking group; R' is selected from the group consisting of hydrogen, C_{1-8} aliphatic hydrocarbon groups, aryl groups and C_{1-8} aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R_1 and R_2 are separately selected from hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group.

17. A pharmaceutical composition according to claim 16, wherein said molecular backbone linking group additionally bears chelating functional units selected from the group consisting of: amino acetic acid, catechols, 2,3-dihydroxyterephthalamides, and hydroxamic acids.

18. A method of removing actinides and iron from a mammalian body which comprises administration of a physiologically acceptable amount of a chelating agent selected from the group consisting of:



wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; R is a molecular backbone linking group; R' is selected from the group consisting of hydrogen, C_{1-8} aliphatic hydrocarbon groups, aryl groups and C_{1-8} aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R_1 and R_2 are separately selected from hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group.

19. A method according to claim 18, wherein said molecular backbone linking group is of linear, branched linear, multipodal or macrocyclic topology.

20. A method according to claim 19, wherein said molecular backbone linking group additionally bears at least one chelating functional unit selected from the group consisting of:



or mixtures thereof, wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; an amide free valency is the point of attachment to said

molecular backbone linking group; R' is selected from the group consisting of hydrogen, C_{1-8} aliphatic hydrocarbon groups, aryl groups and C_{1-8} aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R_1 and R_2 are separately selected from hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group.

21. A method according to claim 20, wherein said molecular backbone linking group additionally bears chelating functional units selected from the group consisting of: amino acetic acid, catechols, 2,3-dihydroxyterephthalamides, and hydroxamic acids.

22. A method of removing actinides and iron from a mammalian body which comprises administration of a pharmaceutical composition comprising the chelating agent selected from the group consisting of:



,


or


wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; R is a molecular backbone linking group; R' is selected from the group consisting of hydrogen, C_{1-8} aliphatic hydrocarbon groups, aryl groups and C_{1-8} aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R_1 and R_2 are separately selected from hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group, together with a physiologically acceptable diluent or carrier.

23. A method of removing actinides and iron from a mammalian body which comprises administration of a pharmaceutical composition according to claim 22 which further comprises a solid carrier and is in a form suitable for oral administration.

24. A method according to claim 23, whereln said molecular backbone linking group is of linear, branched linear, multipodal or macrocyclic topology.

25. A method according to claim 24, wherein said molecular backbone linking group additionally bears at least one chelating functional unit selected from the group consisting of:



,


,


,

or mixtures thereof, wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; an amide free valency is the point of attachment to said molecular backbone linking group; R' is selected from the group consisting of hydrogen, C_{1-8} aliphatic hydrocarbon groups, aryl groups and C_{1-8} aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R_1 and R_2 are separately selected from hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group.

26. A method according to claim 25, wherein said molecular backbone linking group additionally bears chelating functional units selected from the group consisting of: amino acetic acid, catechols, 2,3-dihydroxyterephthalamides, and hydroxamic acids.

27. MRI diagnosis agents containing complexes of chelating agents selected from the group consisting of:


,

or


wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; R is a molecular backbone linking group; R' is selected from the group consisting of hydrogen, C_{1-8} aliphatic hydrocarbon groups, aryl groups and C_{1-8} aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R_1 and R_2 are separately selected from hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group.

28. MRI diagnosis agents according to claim 27, wherein said molecular backbone linking group is of linear, branched linear, multipodal or macrocyclic topology.

29. MRI diagnosis agents according to claim 28, wherein said molecular backbone linking group additionally bears at least one chelating functional unit selected from the group consisting of:


,

,

,

or mixtures thereof, wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; an amide free valency is the point of attachment to said molecular backbone linking group; R' is selected from the group consisting of hydrogen, C_{1-8} aliphatic hydrocarbon groups, aryl groups and C_{1-8} aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R_1 and R_2 are separately selected from hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group.

30. MRI diagnosis agents according to claim 29, wherein said molecular backbone linking group additionally bears chelating functional units selected from the group consisting of: amino acetic acid, catechols, 2,3-dihydroxyterephthalamides, and hydroxamic acids.

31. An improved process of synthesizing 3-hydroxy-1-alkyl-2(1H)-pyridinone comprising the steps:

(1) heating a mixture of 2,3-dihydroxypyridine and iodoalkane in a closed, explosion resistant, sealable container to create an oil;

(2) mixing said oil with inorganic sulfite salt and water to create a solution;

(3) neutralizing said solution,

(4) filtering said solution;

(4) extracting said solution to create an extract;

(5) purifying said extract with a flash silica gel plug to create a purified extract; and

(6) evaporating said purified extract.

32. A process of synthesizing 4-carboxy-3-hydroxy-2(1H)-pyridinones of the following formula,



comprising the steps:

(1) mixing 3-hydroxy-2(1H)-pyridinones and anhydrous potassium carbonate in about 1:3 to 1:5 mol ratio to create a mixture;

(2) placing said mixture in a closed, explosion resistant, sealable container and filling with dry carbon dioxide gas to about 600-900 psi;

(3) heating said mixture to about 170-200° C for about 24-72 hours;

(4) cooling said mixture to create a solid; and

(5) dissolving said solid in water to create a solution;

(6) acidifying said solution with mineral acid to create an acidified solution; and

(7) filtering said acidified solution to create said 4-carboxy-3-hydroxy-2(1H)-pyridinones.

33. A process of synthesizing hydroxypyridinone chelating agents selected from the group consisting of:



,



or



wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; R is a backbone linking group; R' is selected from the group

consisting of hydrogen, C_{1-8} aliphatic hydrocarbon groups, aryl groups and C_{1-8} aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R_1 and R_2 are separately selected from hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group, wherein said molecular backbone linking group is of linear, branched linear, multipodal or macrocyclic topology and said molecular backbone linking group bears a combination of said chelating functional units, comprising the steps:

(1) reacting an acid selected from the group consisting of:





or

with a hydroxy group protecting agent to create a protected HOPO carboxylic acid;

(2) converting said protected HOPO carboxylic acid to an activated species, which is selected from the group consisting of an activated ester, an activated amide, or an acid chloride;

(3) reacting said activated species with a backbone amine to create a hydroxy-protected chelating agent; and

(4) deprotecting said hydroxy-protected chelating agent to generate said hydroxypyridinone chelating agent.

34. A process of synthesizing bidentate and multidentate hydroxypyridinone chelating agents selected from the group consisting of:


,

or


wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; R is a backbone linking group; R' is selected from the group consisting of hydrogen, C_{1-8} aliphatic hydrocarbon groups, aryl groups and C_{1-8} aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R_1 and R_2 are separately selected from hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group, comprising the steps:

(1) mixing an acid selected from the group consisting of:


,

or


with a hydroxy group protecting agent in 1:1.2 mol ratio and excess anhydrous potassium carbonate in a suitable solvent to create a first mixture;

(2) heating said first mixture at about 65-80° C under N_2 in darkness for about 16 hours,

(3) filtering said first mixture to create a filtrate;

(4) evaporating said filtrate to create an oil;

(5) mixing said oil with a solution of mineral base for about 4-8 hours to create a second mixture;

(6) evaporating said second mixture to dryness to create a solid;

(7) dissolving said solid in water to create a solution;

(8) acidifying said solution with mineral acid to precipitate a solid acid;

(9) converting said solid acid to activated amide, acid chloride or activated ester;

(10) mixing said activated amide, acid chloride or activated ester with a proper backbone amine in a proper solvent for about 4-8 hours to create a raw protected ligand;

(11) purifying said raw protected ligand to create a protected ligand;

(12) deprotecting said protected ligand with a suitable acid or catalytic hydrogenation and filtration to create a filtrate;

(13) evaporating said filtrate to create a residue;

(14) recrystallizing said residue with a suitable solvent to obtain a pure hydroxypyridinone chelating agent.


C1
C19
C2
C10
N1
C20
C11
O1
O4
N6
C21
O7
C3
N2
N4
C12
C13
O2
O5
O8
C22
C27
C9
C4
C5
C23
C8
C6
C24
N7
C26
N3
N5
O6
O3
O9
C7
C16
C25

FIG. 1.


Cl8
C9
C27
C26
O6
Cl7
N1
C8
O3
O9
Cl6
N3
N4
C7
N2
C25
C5
C15
C6
Cl4
C4
O4
C1
O1
O7
C24
C10
N5
C2
C19
C23
Cl3
C3
C11
O2
O10
N6
C20
C22
O5
O8
N7
O11
Cl2
C21

FIG. 2.

INTERNATIONAL SEARCH REPORT

Intern. al Application No
PCT/US 95/07766

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D213/81 C07D213/89 C07C233/77 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,4 698 431 (RAYMOND KENNETH N ET AL) 6 October 1987 cited in the application see column 3, line 35 - column 6, line 40; examples 2-12 ---	1-34
A	US,A,4 666 927 (HIDER ROBERT C ET AL) 19 May 1987 cited in the application see the whole document --- -/--	1-34

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
27 December 1995	-4. 01. 96

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016	Bosma, P

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Intern. al Application No
PCT/US 95/07766

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 14, 7 July 1995 WASHINGTON US, pages 2606-2614, J. XU ET AL. 'Specific sequestering agents for the actinides. 28. Synthesis and initial evaluation of multidentate 4-carbamoyl-3-hydroxy-1-methyl-2(1H)-pyridinone ligands for in vivo plutonium(IV) chelation.' see the whole document	1-34
X	CHEMICAL ABSTRACTS, vol. 122, no. 1, 2 January 1995 Columbus, Ohio, US; abstract no. 4449p, P. DURBIN ET AL. 'In vivo chelation of Am(III), Pu(IV), Np(V) and U(VI) in mice by TREN-(Me-3,2-HOPO).' page 517; see abstract; CAS RN 159356-07-7 & RADIATION PROTECTION DOSIMETRY. , vol. 53, no. 1-4, 1994 ASHFORD, ENGL., pages 305-309, ---	1-34
X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 4, 1993 WASHINGTON US, pages 504-509, L.C. UHLIR ET AL. 'Specific sequestering agents for the actinides. 21. Synthesis and initial biological testing of octadentate mixed catecholate-hydroxypyridinonate ligands.' see compound 3; Figure 1 see table I ---	1-30
X	CHEMICAL ABSTRACTS, vol. 105, no. 25, 22 December 1986 Columbus, Ohio, US; abstract no. 221872z, R.J. BERGERON ET AL. 'Catecholamide chelators for actinide environmental and human decontamination.' page 374; see abstract & CHEMICAL SEPARATIONS, DEVELOPED FROM SELECTED PAPERS PRESENTED AT THE INTERNATIONAL CONFERENCE ON SEPARATIONS SCIENCE AND TECHNOLOGY, 1ST, NEW YORK, 1986, vol. 2, 1986 DENVER, pages 123-127, --- -/--	1,13,18, 22,27

1

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Intern al Application No
PCT/US 95/07766

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 101, no. 15, 8 October 1984 Columbus, Ohio, US; abstract no. 125980e, P.W. DURBIN ET AL. 'Specific sequestering agents for the actinides: Enhancement of plutonium-238 elimination from th emice by poly(catechoylamide) ligands.' page 328; see CAS RN 69146-59-4 see abstract & RADIATION RESEARCH, vol. 99, no. 1, 1984 NEW YORK, pages 85-105, ---	1,13,18, 22,27
X	CHEMICAL ABSTRACTS, vol. 92, no. 13, 31 March 1980 Columbus, Ohio, US; abstract no. 106582f, R.A. BULMAN ET AL. 'An examination of some complexing agents for ability to remove intracellularly deposited plutonium.' page 286; see CAS RN 16414-49-6 see abstract & HEALTH PHYSICS, vol. 37, no. 6, 1979 NEW YORK, pages 729-934, ---	1,13,18, 22,27
X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 6, 1990 WASHINGTON US, pages 1749-1755, M. STREATER ET AL. 'Novel 3-hydroxy-2(1H)-pyridinones. Synthesis, Iron(III)-chelating properties, and biological activity.' see Scheme I -----	31

1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/07766

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 18-26 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The subject matter of the present claims 1, 13, 18, 22 and 27 is so broad that a complete search is not possible on economic grounds (PCT Search Guidelines III, 3.5 and 3.7). Therefore the search has been based on the examples and the claims as indicated.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern :l Application No
PCT/US 95/07766

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-4698431	06-10-87	NONE		
US-A-4666927	19-05-87	DE-D-	3486255	20-01-94
		DE-T-	3486255	24-03-94
		EP-A,B	0138421	24-04-85
		EP-A-	0357150	07-03-90
		GB-A,B	2146989	01-05-85
		JP-C-	1880001	21-10-94
		JP-B-	6002739	12-01-94
		JP-A-	60094965	28-05-85
		JP-A-	2191254	27-07-90
		JP-B-	6002740	12-01-94
		US-A-	5104865	14-04-92
		US-A-	4863913	05-09-89
		US-A-	4912118	27-03-90